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ABSTRACT 
This document provides guidance to applicants for submitting an application for authorisation of genetically 
modified (GM) plants for food and feed uses, import and processing, and/or cultivation in the European Union 
under Regulation (EC) No 1829/2003. The EFSA submission guidance describes the community procedures in 
the European Union for handling GM plant applications, and provides instructions  to applicants on how to 
prepare and present data in an application. It is supplemented with seven appendices providing templates of data 
presentation to be followed by applicants, including a completeness checklist. The earlier versions are now 
updated to account for requirements outlined in Implementing Regulation (EU) No 503/2013. Instructions for 
submission  described  in  this  EFSA  guidance  are  applicable  to  all  GM  plant  applications  submitted  under 
Articles 5, 11, 17 and 23 of Regulation (EC) No 1829/2003. 
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SUMMARY 
The EFSA submission guidance provides guidelines for handling applications for authorisation of 
genetically modified (GM) plants for food and feed uses, import and processing, and/or cultivation 
(referred  to  hereafter  as  “GM  plant  applications”)  in  the  European  Union  (EU),  submitted  under 
Regulation (EC) No 1829/2003. It consists of the following five chapters: 
  Chapter 1 describes the EU procedure for handling GM plant applications; 
  Chapter 2 provides detailed instructions on the structure of an application and the presentation 
of data in the desired format; 
  Chapter 3 explains specific requirements for different parts of an application, in particular, 
Parts I, II and VIII; 
  Chapter 4 explains  requirements  specific to applications  concerning  GM  plants  containing 
stacked events. 
  Chapter 5  explains  requirements  specific  for  GM  plants  application  for  renewal  of 
authorisation. 
Instructions described in the EFSA submission guidance are applicable to all GM plant applications 
submitted under Articles 5, 11, 17 and 23 of Regulation (EC) No 1829/2003. 
The EFSA submission guidance is supplemented by seven appendices: 
  Appendix A is a completeness checklist to be filled by applicants; 
  Appendix B  provides  templates  to  summarise  scientific  information  as  well  as  exemplar 
figures for data presentation; 
  Appendix C  specifies  data  to  be  provided  for  the  comparative  analysis  of  the  GM  plant 
agronomic/phenotypic characteristics; 
  Appendices D-F specify data to be provided for the environmental risk assessment (ERA); 
  Appendix G is the proof of reception issued by the EU Reference Laboratory for GM Food 
and Feed; 
The abovementioned appendices should be filled out and submitted by applicants. These are then 
checked by EFSA to ensure that: (i) all necessary information and documentation specified by this 
submission guidance, is present in the data package; and (ii) an application data package conforms 
with the recommended structure and format.  
The EFSA submission guidance is now updated to account for requirements outlined in Implementing 
Regulation (EU) No 503/2013. This Regulation only covers GM plant applications for food and feed 
uses, and excludes GM plant applications for cultivation in the EU. Therefore, the update of the EFSA 
submission guidance focuses on the relevant parts related to molecular characterisation and food and 
feed safety assessment as outlined in Appendix A (the completeness checklist). Parts pertaining to the 
ERA were not changed, except for Appendix E that was updated. 
The EFSA submission guidance and appendices are available in electronic format on EFSA website. 
 EFSA submission guidance for GM plant applications  
 
EFSA Journal 2013;11(12):3491  3 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 3 
Background .............................................................................................................................................. 4 
Terms of reference as provided by EFSA ................................................................................................ 4 
Guidance  ................................................................................................................................................... 5 
1.  Procedure for handling GM plant applications in the EU ............................................................... 5 
1.1.  Submission of an application .................................................................................................. 5 
1.2.  Submission to an institute developing certified reference materials  ....................................... 5 
1.3.  Submission to the European Union Reference Laboratory for GM Food and Feed ............... 5 
1.4.  Receipt of the application by EFSA  ........................................................................................ 7 
1.5.  Completeness check by EFSA ................................................................................................ 7 
1.6.  Validation of application by EFSA ......................................................................................... 7 
1.7.  Risk assessment, MS comments and request for additional information  ................................ 8 
1.7.1.  Member States comments  ................................................................................................... 8 
1.7.2.  Request for additional information ..................................................................................... 8 
1.7.3.  Adoption of a scientific opinion by the EFSA GMO Panel ............................................... 9 
1.8.  Networking with Member States on GM plant applications for cultivation ........................... 9 
1.9.  EFSA overall opinion ............................................................................................................. 9 
1.10.  Withdrawal of GM plant applications  ................................................................................... 10 
2.  Preparation of GM plant applications ............................................................................................ 10 
2.1.  Structure of GM plant applications ....................................................................................... 10 
2.1.1.  Submission version ........................................................................................................... 11 
2.1.2.  Public access version ........................................................................................................ 12 
2.2.  Language ............................................................................................................................... 12 
2.3.  Electronic version ................................................................................................................. 12 
2.3.1.  Format and label of the CD-ROMs .................................................................................. 12 
2.3.2.  File format, size and name  ................................................................................................ 12 
2.4.  Standard units and abbreviations .......................................................................................... 13 
3.  Specifics on the different parts of the application ......................................................................... 13 
3.1.  Part I – General information ................................................................................................. 13 
3.2.  Part II – Scientific information ............................................................................................. 13 
3.2.1.  Content and requirement of Part II ................................................................................... 13 
3.2.2.  Data presentation – figures and tables .............................................................................. 14 
3.2.3.  Citations and reference list ............................................................................................... 15 
3.3.  Part III – Cartagena protocol  ................................................................................................. 16 
3.4.  Part IV – Labelling  ................................................................................................................ 16 
3.5.  Part V – Methods of detection, sampling and identification and reference material ............ 16 
3.6.  Part VI – Additional information to be provided for GM plants and/or food/feed containing 
or consisting of GM plants ................................................................................................................. 17 
3.7.  Part VII – Summary of applications ..................................................................................... 17 
3.8.  Part VIII -Administrative documents  .................................................................................... 17 
3.8.1.  Letter “consent of access” ................................................................................................ 17 
3.8.2.  Completeness checklist  ..................................................................................................... 17 
4.  Applications for GM plants containing stacked events ................................................................. 17 
5.  Applications for renewal authorisations ........................................................................................ 18 
Useful websites ...................................................................................................................................... 18 
References .............................................................................................................................................. 18 
Appendices ............................................................................................................................................. 20 
Abbreviations ......................................................................................................................................... 21 EFSA submission guidance for GM plant applications  
 
EFSA Journal 2013;11(12):3491  4 
BACKGROUND  
Genetically modified organisms (GMOs) and derived food and feed products are subject to a risk 
analysis  and  regulatory  approval  before  entering  the  European  market.  Regulation  (EC) 
No 1829/2003
5  lays  down  the  community  procedures  in  the  European  Union  (EU)  for  the 
authorisation and supervision of genetically modified (GM) food and feed, as well as for the labelling 
of such food and feed. In this process, the role of the European Food Safety Authority (EFSA) is to 
independently  assess,  providing  scientific  advice  to  risk  managers,  any  possible  risks  that  the 
consumption or cultivation of a GMO may pose to human and animal health and the environment. 
In accordance with Articles 5(8), 11(6), 17(8) and 23(6) of Regulation (EC) No 1829/2003, EFSA and 
its GMO Panel are responsible for developing detailed guidance to assist applicants in the preparation 
and presentation of GMO market registration applications. As a first result of this task, the EFSA 
GMO Panel published the Guidance document for the risk assessment of GM plants and derived food 
and  feed,  together  with  four  Annexes (I  to  IV)  providing  instructions  for  the  presentation  of 
applications (EFSA, 2006). 
EFSA  developed  a  Guidance  to  applicants  on  the  preparation  and  presentation  of  GM  plant 
applications (referred to hereafter as “submission guidance”) in 2011, following the update of the 
EFSA GMO Panel Guidance Documents for risk assessment of GM food and feed (EFSA, 2011a) and 
for the ERA of GM plants (EFSA, 2010a). In the following year, EFSA gained significant experience 
in checking the completeness of GM plant applications. This, together with feedback received from 
applicants,  other  stakeholders  and  EU  Member  States,  motivated  a  first  revision  of  this  EFSA 
submission guidance in 2012. 
The  recent  publication  of  Implementing  Regulation  (EU)  No 503/2013
6  necessitates  an  additional 
revision of this EFSA submission guidance, in order to reflect the data requirements outlined in this 
Regulation. Therefore, EFSA decided to align its submission guidance to the requirements of the 
Implementing Regulation (EU) No 503/2013. 
TERMS OF REFERENCE AS PROVIDED BY EFSA 
The  EFSA  submission  guidance  assists  applicants  for  the  preparation  and  presentation  of  an 
application for authorisation of GM plants and derived products for food and feed uses, import and 
processing, and/or seeds and plant propagating material for cultivation in the EU, submitted under 
Articles 5  and  17  of  Regulation  (EC)  No 1829/2003.  This  submission  guidance  applies  also  to 
applications for the renewal authorisation of existing products produced from GM plants submitted 
under Articles 11 and 23 of Regulation (EC) No 1829/2003. 
The  submission  guidance  provides  information  on  the  structure  of  applications,  the  naming  of 
documents, the presentation of reports, data and confidential information. It includes a completeness 
checklist,  reflecting  the  requirements  for  GM  plant  applications  as  outlined  in  the  Implementing 
Regulation (EU) No 503/2013 and the EFSA GMO Panel Guidance document for the environmental 
risk assessment of GM plants. The completeness checklist should be filled by applicants, then checked 
by EFSA to ensure that (i) GM plant applications follow the required structure; and (ii) all required 
information and documents are provided. 
SCOPE OF THE EFSA SUBMISSION GUIDANCE 
EFSA requested its GMO Unit to align the EFSA submission guidance to the requirements outlined in 
the Implementing Regulation (EU) No 503/2013. 
                                                       
5  Regulation  (EC)  No 1829/2003  of  the European Parliament  and  of  the  Council  of  22 September  2003 on  genetically 
modified food and feed. OJ L 268, 18.10.2003, p. 1–23. 
6 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically 
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council 
and amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L 157, 8.6.2013, p. 1-48 EFSA submission guidance for GM plant applications  
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GUIDANCE 
1.  Procedure for handling GM plant applications in the EU 
One  objective  of  Regulation  (EC)  No 1829/2003  is  to  lay  down  community  procedures  for  the 
authorisation and supervision of GM food and feed in the EU. The different steps of handling GM 
plant  applications  submitted  under  Regulation  (EC)  No 1829/2003  are  illustrated  in  Figure 1  and 
explained in Sections 1.1 to 1.10. 
1.1.  Submission of an application 
In accordance with Articles 5(2) and 17(2) of Regulation (EC) No 1829/2003, applicants shall submit 
their GM plant applications. The MS CA shall acknowledge receipt of the application to the applicant 
in writing within 14 days of its receipt. The acknowledgement shall state the date of receipt of the 
application. The MS CA shall, without delay, inform EFSA and  forward the application and any 
supplementary information supplied by the applicant to EFSA. 
In accordance with Articles 11(1) and 23(1) of Regulation (EC) No 1829/2003, GM plant applications 
for the renewal authorisation shall be sent to the European Commission (EC) at least one year before 
the expiry date of the authorisation. The EC then mandates EFSA to assess the renewal application. 
1.2.  Submission to an institute developing certified reference materials 
In accordance to Articles 5(3)(j) and 17(3)(j) of Regulation (EC) No 1829/2003, reference materials 
must be developed. Applicants shall submit samples of the food and feed and their controls to the 
institute that is responsible for the production of certified reference materials (CRM). A statement that 
the  certified  reference  materials  are  produced,  in  accordance  to  Annex II  of  Regulation  (EC) 
No 641/2004, should be included in the GM plant application under Part V (see Section 3.5). 
1.3.  Submission to the European Union Reference Laboratory for GM Food and Feed 
In accordance with Article 32 and the Annex of Regulation (EC) No 1829/2003, the European Union 
Reference Laboratory for GM Food and Feed (EURL-GMFF), formerly named Community Reference 
Laboratory, is the Commission‟s Joint Research Centre. EURL-GMFF is responsible for the validation 
of methods for sampling, detection and identification of the GM food and feed. After evaluation, the 
EURLGMFF submits its full evaluation report to EFSA. 
The EURL-GMFF examines the completeness of the information related to the presence of samples 
and detection methods. More information on the requirements can be consulted at its website. 
During the completeness check of GM plant applications (see Section 1.5) EFSA verifies that a proof 
of submission of the samples, reagents and methods issued by the EURL-GMFF is provided in the 
application. Therefore, EFSA recommends the applicant to submit documents and samples to EURL-
GMFF before submitting GM plant applications to the MS CA, so that the proof of reception by the 
EURL-GMFF can be readily included in the application (see Appendix G). 
 EFSA submission guidance for GM plant applications  
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Figure 1:  Steps for handling GM plant applications submitted under Regulation (EC) No 1829/2003. Figure 1 is organised in three parts: The left part 
consists of grey boxes representing the successive steps for handling GM plant applications. The central part of the figure depicts the process as flowchart with arrows indicating the 
information flow between the different actors involved; blue arrows represent steps specific for GM plant applications for food and feed uses, import and processing, while green arrows 
indicate the additional steps for GM plant applications for cultivation. The right part of the figure consists of blue boxes describing the type of deliverables. The dashed lines specify who 
is  responsible  for  producing  the  respective  deliverables.  Note  that  not  all  steps  are  applicable  to  each  GM  plant  application.  Abbreviations:  EC:  European  Commission;  ERA: 
environmental risk assessment; EURL-GMFF: European Union‟s Reference Laboratory for GM Food and Feed; MS CA: national Competent Authority of a Member State. EFSA submission guidance for GM plant applications  
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1.4.  Receipt of the application by EFSA 
Correspondence to EFSA concerning GM plant applications should be addressed to: 
European Food Safety Authority 
Head of Applications Desk Unit  
Via Carlo Magno 1A 
43126 Parma  
Italy 
E-mail: APDESK.applications@EFSA.europa.eu 
The Applications Desk Unit is responsible for the registration of market applications for regulated 
products in EFSA, and is the contact point for applicants until the GM plant application is validated. In 
accordance with Articles 5(2) and 17(2) of Regulation (EC) No 1829/2003, once the MS CA forwards 
a GM plant application to EFSA, EFSA acknowledges the receipt of the application to the MS CA. 
EFSA, without delay, informs the other MS CA and EC. EFSA endeavours to make the summary of 
GM plant applications available to the public through the Register of Questions within two weeks 
following reception. Via its electronic system, known as the EFSA GMO Extranet, EFSA makes the 
summary of GM plant applications available to: EFSA GMO Panel and its standing Working Groups 
(WGs); EC; and all MS CA. 
1.5.  Completeness check by EFSA 
At reception, a GM plant application is given an identification code. This code should be included in 
all further correspondence with EFSA, the EURL-GMFF and EC. After reception Applications Desk 
Unit, with the technical support of GMO Unit, checks the completeness of the application (Figure 1) 
and  validates  it  when  it  fulfils  the  legal  requirements  outlined  in  Implementing  Regulation  (EU) 
No 503/2013. EFSA endeavours to have the first outcome of the completeness check available within 
30 working days after the reception date. 
The completeness check process might require further exchange of information between the applicant 
and EFSA. In such case, EFSA informs the applicant, in writing, if certain parts of the GM plant 
application  need  modification  or  completion,  in  order  to  proceed  to  validation.  After  receiving  a 
request for additional information, the applicant should submit the response within 30 days. When this 
is not possible, the applicant should indicate to EFSA the date by which the response is expected. 
EFSA will notify the acceptance of the new submission date via e-mail. 
When responding to EFSA questions, the applicant should submit an updated version of the entire GM 
plant application (Parts I to VIII) on CD-ROM(s). EFSA advises to accompany the submission of an 
updated GM plant application with a cover letter wherein the applicant precisely describes how each 
EFSA question was addressed. Missing information should be incorporated in all relevant parts of the 
GM plant application. EFSA endeavours to inform the applicant within 15 working days if the updated 
GM plant application is complete or if further revision is required. 
1.6.  Validation of application by EFSA 
Once the GM plant application fulfils all requirements, EFSA issues a validity statement. The valid 
GM plant application is then made available to all MS CAs and the EURL-GMFF via EFSA GMO 
Extranet. Upon validity, EFSA updates the summary (Part VII) of the GM plant application on the 
publicly accessible EFSA Register of Questions.  
With the validity statement, the applicant is requested to submit one paper copy of the valid GM plant 
application  and  one  electronic  copy  of  the  public  access  version  (see  Section 2.2)  to  EFSA.  The 
applicant shall confirm by letter that this paper copy is identical to the validated electronic version of 
the GM plant application. At this stage, EFSA does not accept any further modification of the GM 
plant application other than editorial ones. EFSA may request additional electronic and paper copies of EFSA submission guidance for GM plant applications  
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the valid version. As stated in the validity statement, after validation, EFSA GMO Unit becomes the 
point of contact for applicants.  
All information provided by the applicant is available on the EFSA GMO Extranet. EFSA informs 
registered GMO Extranet members about the updates of GM plant applications via e-mail on a weekly 
basis. This  includes  correspondence  such as  declarations  of  validity,  questions  sent  to  applicants, 
responses from applicants, spontaneously submitted information from applicants, as well as calls for 
„expression  of  interest‟  to  all  MS  CA  designated,  in  accordance  with  Article 4  of  Directive 
2001/18/EC
7, to perform the initial ERA of GM plant applications for cultivation. 
1.7.  Risk assessment, MS comments and request for additional information 
From the date of validity, GM plant applications enter the risk assessment phase in accordance with 
Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003. The EFSA GMO Panel is supported by 
three  WGs,  each  focusing  on  specific  areas  of  the  risk  assessment:  the  WG  on  Molecular 
Characterisation (MC) considers all relevant scientific data on the molecular characterisation of the 
GM  plant,  such  as  detailed  information  on  the  source  and  function  of  the  donor  DNA,  the 
transformation  method,  the  organisation  of  the  inserted  DNA  at  the  insertion  site(s),  and  the 
expression and stability of the insert. The WG on Food/Feed Risk Assessment (FF) focuses on the 
agronomic and phenotypic characteristics, composition, toxicity, allergenicity and nutritional value of 
the GM plant and its derived food and feed. The WG on Environmental Risk Assessment (ENV) 
considers elements such as changes in interactions with biotic and abiotic  factors, changes in the 
persistence (weediness) and invasiveness ability of the GM plant, potential for gene transfer and its 
environmental consequences, interactions between the GM plant and target and non-target organisms, 
effects  on  biogeochemical  processes,  as  well  as  impacts  of  specific  cultivation,  management  and 
harvesting techniques associated with the cultivation of the GM plant.  
GM plant applications are discussed in the three WGs mentioned above and the outcomes of such 
discussions are summarised in the respective WG meeting minutes. EFSA endeavours to send the first 
questions identified within two and half months after the date of validity. 
In accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA shall endeavour 
to  respect  a  time  limit  of  six  months,  from  the  validity  date  of  a  GM  plant  application  to  the 
publication of the EFSA overall opinion in the EFSA Register of Questions (see Section 1.9). 
1.7.1.  Member States comments 
Within three months following the date of validity, all MS CA can submit to EFSA, via the EFSA 
GMO Extranet, comments or questions on valid GM plant applications under assessment. The three 
WGs consider all MS comments submitted during this consultation period and provide a response to 
each comment. These are published as Annex G of the EFSA overall opinion (see Section 1.9). 
1.7.2.  Request for additional information 
EFSA  may  request  additional information  in  order to  clarify  specific  risk  assessment  issues. The 
rationale for asking a question is provided to applicants. A question raised will not be reiterated. As 
outlined  in  Articles 6(1)  and  18(1)  of  Regulation  (EC)  No 1829/2003,  the  request  for  additional 
information extends the six-month time limit (known as the “stop-the-clock” mechanism). 
After receiving a request for additional information, the applicant should submit the response within 
30 working days. When this is not possible, the applicant should indicate to EFSA the date by which 
the response is expected. EFSA will notify the acceptance of the new submission date via e-mail. If, in 
exceptional cases, the agreed timeline cannot be met, the applicant should immediately inform EFSA. 
                                                       
7 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC – Commission declaration. 
OJ L 106, 17.4.2001, p. 1–39. EFSA submission guidance for GM plant applications  
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A  request  for  additional  information  may  address  several  parts  of  a  GM  plant  application.  The 
applicant  is  asked  to  provide  one  complete  answer  addressing  all  issues  raised.  If  the  additional 
information raises new questions, EFSA will send a letter to the applicant with the new questions and 
the clock remains stopped. If the additional information does not raise new questions, EFSA will 
restart the clock and inform the applicant in writing.  
The  additional  information  should  be  provided  in  electronic  form.  If  confidential  information  is 
included (see Section 2.1.2) a public access version should also be provided. In addition, the overview 
table on studies and relevant figures should be updated (see Appendix B). 
Additional information may also be requested by the EURL-GMFF. EFSA will stop the clock for the 
clarification on or provision of any elements required under Articles 6(1) and 18(1) of Regulation 
(EC) No 1829/2003.  
Requests for additional information may also come from the MS CA carrying out the initial evaluation 
of the ERA for GM plant applications for cultivation. In this case, the lead MS CA asks EFSA to stop 
the clock with additional questions to the applicant. EFSA then proceeds with the request by informing 
the applicant in writing, including the letter of this MS CA in an annex. 
1.7.3.  Adoption of a scientific opinion by the EFSA GMO Panel  
During the risk assessment phase the WGs prepare a scientific opinion for a GM plant application, 
which  is  discussed,  amended  and  adopted  by  the  EFSA  GMO  Panel  at  plenary  meetings.  EFSA 
endeavours to publish the scientific opinion in the EFSA Journal within three weeks from the date of 
adoption. 
1.8.  Networking with Member States on GM plant applications for cultivation 
If a GM plant application involves the cultivation of the GM plant (as seeds or other plant-propagating 
material)  in  the  EU,  EFSA  shall  ask  a  MS  CA  to  perform  the  initial  ERA,  in  accordance  to 
Articles 6(3)  and  18(3)  of  Regulation  (EC)  No 1829/2003..In  such  cases,  EFSA  will  call  for 
„expressions  of  interest‟  from  all  MS  CA,  designated  in  accordance  with  Article 4  of  Directive 
2001/18/EC. EFSA will select a MS CA on the basis of the following criteria: 
(i)  experience in performing ERA; 
(ii)  experience in writing national risk assessment reports; 
(iii)  interest in the crop/trait; 
(iv)  availability.  
If no MS CA expresses an interest, a formal request will be addressed to the MS CA to which the GM 
plant application was submitted. 
The selected MS CA will carry out the initial ERA by following the EFSA GMO Panel Guidance on 
the ERA of GM plants (EFSA, 2010a) and will work in close contact with EFSA. After finalising its 
evaluation, the MS CA submits its ERA report to EFSA. This report will be considered by the EFSA 
GMO Panel before adopting its scientific opinion, and will be included as Annex H of the EFSA 
overall opinion (see Section 1.9). 
1.9.  EFSA overall opinion 
The EFSA overall opinion is prepared when all parts are finalised, as mentioned in Article 6(5) and 
18(5) of Regulation (EC) No 1829/2003. In accordance with Articles 6(7) and 18(7) of Regulation 
(EC) No 1829/2003, EFSA makes the overall opinion available to the public through its Register of 
Questions. EFSA submission guidance for GM plant applications  
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The overall opinion includes the following annexes as applicable: 
Annex A   Scientific opinion of the EFSA GMO Panel 
Annex B   Compliance report for the Cartagena Protocol (from the applicant) 
Annex C   Labelling proposal (from the applicant) 
Annex D1   Validation report (from EURL-GMFF) 
Annex D2   Validated method report (from EURL-GMFF) 
Annex D3   Sampling and extraction report (from EURL-GMFF) 
Annex E   Certified Reference Materials report (from the assigned institute) 
Annex F   Monitoring plan (from the applicant) 
Annex G   Comments from MS CAs and replies from the EFSA GMO Panel  
Annex H   MS CA ERA report for GM plant applications (only for cultivation) 
In accordance with Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003, EFSA sends the overall 
opinion to the EC and EURL-GMFF, and informs all MS CA and the applicant. The EFSA scientific 
opinion on GM plant applications is then passed to the EC and EU Member States. The application 
now  enters  the  risk  management  phase  including  the  adoption  of  a  decision.  The  authorisation 
procedure can be found at the DG SANCO website. The status of the decision on authorisation can be 
found in the EU register of genetically modified food and feed. 
1.10.  Withdrawal of GM plant applications 
If an applicant wishes to withdraw its GM plant application during the completeness check or risk 
assessment phase, the applicant should request EFSA in writing for withdrawal, putting in copy EC 
and the MS CA to which the GM plant application was submitted. This letter will be made available 
on the EFSA Register of Questions. 
2.  Preparation of GM plant applications 
2.1.  Structure of GM plant applications 
To submit an application, the applicant should send a paper and an electronic (CD-ROM) copy to the 
national Competent Authority of a Member State (MS CA). Such application should consist of eight 
parts: Part I through Part VII are defined by Implementing Regulation (EU) No 503/2013; Part VIII is 
required by EFSA. Documents should be named and organised in folders as illustrated in Table 1. 
EFSA does not accept parts of GM plant applications submitted by different applicants, nor does 
EFSA compile information submitted by different applicants to obtain one complete application for a 
GM plant. EFSA submission guidance for GM plant applications  
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Table 1:   Overview of the required structure and folder/file names 
Folder name  File name and sub-folder name 
 Part_I_General_info                  General_info.pdf 
 Part_II_Scientific_info              Main_text_[Application_identification code].pdf 
PMEM_Plan.pdf 
 References
1  
 Appendices
2,3 
 ERA Appendices D to F
 
 Part_III_Cartagena_Protocol    Cartagena.pdf 
 Part_IV_Labelling  Proposal                  Labelling.pdf  
 Part_V_Sampling and Detection         Sampling and Detection.pdf 
EURL_proof_submission.pdf (Appendix G) 
 Part_VI_Additional_info  Additional_info.pdf 
 Part_VII_Summary of applications         Summary_[Application_number].pdf 
 Part_VIII_Administrative_doc  See Section 3.8 
1All published documents cited in the main text of the application shall be present in subfolder References and formatted as 
indicated in Section 3.2.3. 
2All unpublished documents provided by the applicant and cited in the main text of the application shall be present in the 
subfolder Appendices and formatted as indicated in Section 3.2.3. 
3In  case  unpublished  studies  of  the  applicant  are  classified  as  CI  and  non-CI,  two  sub-folders  should  be  provided: 
“Appendices  (CI)”  and  “Appendices  (non-CI)”.  If  the  Appendices  folder  is  not  labelled  with  CI  or  non-CI,  all 
documents within that folder will be considered being non-CI. 
2.1.1.  Submission version 
The  electronic  copy  of an  application  should contain  all information  and  should  be  structured  as 
indicated in Table 1. The applicant can choose to either divide confidential (CI) and non-confidential 
(non-CI) information into separate CD-ROMs, or to include them on the same CD-ROM. Each CD-
ROM containing CI should be labelled as described in Section 2.4. In case a CD-ROM is password 
protected, the password should be provided. 
The paper copy of an application should contain the same information as the electronic version, except 
for:  legal  references  (e.g.  Directive  2001/18/EC,  Regulation  (EC)  No 1829/2003,  etc.),  consensus 
documents  (e.g.  Organisation  for  Economic  Co-operation  and  Development  (OECD),  Codex 
alimentarius, etc.), EFSA outputs (e.g. scientific opinions and statements published previously by the 
EFSA GMO Panel), and scientific articles published in peer-reviewed journals. 
Confidential information: The applicant should indicate which parts of the application are claimed to 
be  confidential  in  accordance  with  Article 2(3)  of  Regulation  (EC)  No 641/2004,  together  with  a 
verifiable  justification  in  accordance  with  Article 30  of  Regulation  (EC)  No 1829/2003.  EC  will 
determine which information can be kept confidential and will inform the applicant and EFSA about 
its decision.  
The  main  text  of  the  application  cannot  contain  confidential  information.  Sections  or  studies 
considered confidential by the applicant should be identified by including CI in brackets in the file 
name, e.g. “Appendix x (CI).pdf” and indicating “CONFIDENTIAL” on the corresponding pages. If 
the name of an author is claimed as confidential, it should not be included in the file name and citation 
(see Section 3.2.3). A list, containing all the names to be treated as confidential, should be included in 
Part VIII (see Table 2). 
When  submitting  additional  information,  the  accompanying  cover  letter  should  always  indicate 
whether such additional information contains confidential information.  EFSA submission guidance for GM plant applications  
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2.1.2.  Public access version 
In accordance with Regulation (EC) No 1049/2001
8 EFSA will grant public access, on request, to the 
non-confidential  parts  of  an  application  after  validity  without  prior  consultation  of  the  applicant. 
Therefore, upon validation, the applicant should provide EFSA with a CD-ROM containing the public 
access version of the application.  
The recommended name for the CD-ROM is “Public_Access_[Application identification code]”. The 
public access version of the application must follow the same structure as the original application (see 
Table 1).  The  public  access  version  should  not  contain  confidential  information  and  it  should  be 
otherwise identical to the validated electronic version. 
During the risk assessment phase, when the additional information to EFSA contains confidential 
information, a public access version should also be submitted. 
Following the confidentiality decision by the EC, the applicant should provide a CD-ROM containing 
the final public access version of the application to EFSA. The CD-ROM should bear the date of the 
confidentiality decision. 
2.2.  Language 
An application should be written in idiomatic English. The text should be carefully checked for errors. 
Peer-reviewed articles and published reports in languages other than English should be accompanied 
by translations of the relevant parts. 
2.3.  Electronic version 
2.3.1.  Format and label of the CD-ROMs 
The provided CD-ROM(s) should be clearly labelled and include the following information:  
  name of the GM plant event and plant species;  
  EFSA application identification code (once provided) 
  name of company;  
  date of submission;  
  submission type: 
o  first submission (CC1) 
o  updated versions (CC2... CCx) 
o  valid version 
o  additional information;  
  CI, non-CI, or public access version; 
  CD-ROM number (applicable only if more than one CD-ROM is submitted per application, 
e.g. “CD-ROM 1 of 2”). 
2.3.2.  File format, size and name 
All documents cited in Part I and Part II should be provided preferably as portable document format 
(PDF), should be accessible to allow reading, printing, word searching and copying of text from the 
file using Adobe
® Acrobat
® Standard software. Text and figures of all parts of an application should 
be fully legible. Other software format types, such as Word, Excel and GenBank, are acceptable for 
specific files and they should fulfil the same criteria as required for PDF files. Sequence information is 
preferably submitted in GenBank format including the annotation information. 
                                                       
8 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to 
European Parliament, Council and Commission documents. OJ L 145, 31.5.2001, p. 43–48. EFSA submission guidance for GM plant applications  
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The documents should be formatted for standard DIN A4 (210 x 297 mm) paper. The recommended 
font of text is Times New Roman or Arial, 11-12 points for normal text and 9-10 points for footnotes. 
All fonts used in the document should be embedded in the PDF files to ensure that they are always 
readable and searchable. 
The size of documents should be limited to 25 MB. In case a study report exceeds 1000 pages the 
applicant should consider dividing into separate documents. If this is not possible, the study report in 
the paper version, doe not need to include long appendices (e.g. raw data), which will be asked by 
EFSA if needed.  
File  names  specified  in  Table  1  should  be  used.  For  other  files,  names  should  be  concise  and 
informative and contain no more than 40 characters including spaces. File and folder names should not 
include the following special characters: \ / : * ? \" < > | #.  
All  documents  should  be  well  structured  and  include  a  table  of  content.  On  each  page  of  the 
application, the file name, company name, GM plant event name, and page number should be included 
in the header or footer. To improve navigation through PDF documents the use of bookmarks and 
hyperlinks is encouraged. 
2.4.  Standard units and abbreviations  
The International System of Units (SI)
9 must be used. For the naming of chemical compounds and for 
chemical quantities, units and symbols, the applicants should follow the International Union of Pure 
and  Applied  Chemistry  (IUPAC)  nomenclature
10.  Gene  and  protein  names  should  respect 
nomenclature  and  style  of  the  relevant  species.  Chemical  substances  (e.g.  herbicide)  should  be 
indicated including the trade name and the active substance. 
It is advisable to use only the GM event name in Part II, but to include also its trade name in Part VII. 
Acronyms  and  abbreviations  should  be  defined  when  first  mentioned  and  should  be  listed  at  the 
beginning of Part II.  
3.  Specifics on the different parts of the application  
3.1.  Part I – General information 
Requirements  on  the  structure  and  content  of  Part I  can  be  found  in  Annex I  of  Implementing 
Regulation  (EU)  No 503/2013.  Part I  is  used  by  EFSA  for  both  completeness  check  (see  the 
corresponding  spread-sheet  in  Appendix A)  and  risk  assessment  purposes.  All  information  should 
include sufficient details and should be clearly referenced. 
3.2.  Part II – Scientific information 
Part II should be structured according to Annex I of Implementing Regulation (EU) No 503/2013. 
Part II  is  used  by  EFSA  for  both  completeness  check  (see  the  corresponding  spread-sheets 
Appendix A) and risk assessment purposes. All requirements of Part II should be addressed in the 
application. The ERA section should be structured according to the EFSA GMO Panel Guidance on 
the ERA of GM plants (EFSA, 2010a). 
3.2.1.  Content and requirement of Part II 
The  scientific  content  of  chapters  and  sections  in  the  document 
“Main_text_[Application_identification code].pdf” (see Table 1) should comply with the requirements 
laid down in Annex II of Implementing Regulation (EU) No 503/2013.  
                                                       
9 http://www.bipm.org/utils/common/pdf/si_brochure_8_en.pdf 
10 http://www.iupac.org/ EFSA submission guidance for GM plant applications  
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Specific topics are addressed in the following EFSA guidance documents:  
  Guidance for risk assessment of food and feed from GM plants (EFSA, 2011a) 
  Guidance on selection of comparators for the risk assessment of GM plants and derived food 
and feed (EFSA, 2011b) 
  Guidance  on  the  post-market  environmental  monitoring  (PMEM)  of  GM  plants  (EFSA, 
2011c) 
  Guidance  on  conducting  repeated-dose  90-day  oral  toxicity  study  in  rodents  on  whole 
food/feed (EFSA, 2011d) 
  Guidance on the ERA of GM plants (EFSA, 2010a) 
  Statistical considerations for the safety evaluation of GMOs (EFSA, 2010b) 
  Scientific opinion on the assessment of allergenicity of GM plants and microorganisms and 
derived food and feed (EFSA, 2010c) 
  Scientific  opinion  on  the  assessment  of  potential  impacts  of  GM  plants  on  non-target 
organisms (EFSA, 2010d) 
  Scientific opinion on guidance for the risk assessment of GM plants used for non-food or non-
feed purposes (EFSA, 2009) 
  Safety and nutritional assessment of GM plants and derived food and feed: The role of animal 
feeding trials (EFSA, 2008) 
Part II should be a complete stand-alone document, containing all information required for the risk 
assessment. The information presented in main text, appendices, tables and figures should be coherent. 
If a requirement of Implementing Regulation (EU) No 503/2013 does not apply for certain part(s) of 
an application, the applicant should justify the omission of such data. All studies are expected to be of 
high  quality  and  quality  assurance  documentations  should  be  provided.  Raw  data  of  all  studies 
performed by the applicant should be provided in a suitable electronic format. 
Appendix C  specifies  data  to  be  provided  for  the  comparative  analysis  of  the  GM  plant 
agronomic/phenotypic characteristics. Appendices D to F refer to the data generated in support of the 
ERA. Appendix D is required for applications on GM plants expressing insect resistance traits. The 
four tables provided in Appendix E should be used to summarise the studies on non-target organisms 
(NTOs) used to support the ERA. Appendix F is required for each experimental study submitted for 
the ERA. All compiled appendices D to F should be saved in the folder Appendices as the subfolder 
ERA_Appendices D to F (see Table 1). 
3.2.2.  Data presentation – figures and tables  
Applicants are encouraged to use figures and tables to illustrate experimental data. The resolution and 
quality of images should be sufficient to enable the non-equivocal interpretation of the data. Examples 
for  MC  and  FF  data  presentation  can  be  found  in  Appendix B.  Schematic  summaries  of  data 
supporting the comparative analysis of the GM plant agronomic/phenotypic characteristics and ERA 
data are given in Appendix C and Appendices D-F, respectively. 
Figure preparation: Each figure  is expected to have a self-explanatory title and a legend, to be 
numbered according to its appearance, and to be cited in the text. No specific feature within an image 
can be enhanced, obscured, moved, removed or introduced.  Adjustment of brightness, contrast or 
colour balance can be applied only to the whole image, provided that this does not obscure, eliminate 
or miss-represent any information. The grouping or consolidation of images from multiple sources 
must be explicitly acknowledged in the figure and in its legend.  EFSA submission guidance for GM plant applications  
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Table preparation: Each table is expected to have a self-explanatory title and a legend as appropriate, 
to be numbered according to the order of its appearance, and to be cited in the text.  
3.2.3.  Citations and reference list 
All published and unpublished studies provided in Part II should be clearly cited. Citations should be 
presented in an alphabetical reference list at the end of the document. Applicants are recommended to 
include also an overview table of all studies and reports carried out at the beginning of the main text. 
An example of such an overview table is provided in Table 1 of Appendix B. 
3.2.3.1.  Published studies, proceedings, reports, guidelines and legislation 
Citations should be derived from file names. Published study should be cited as (Johnson et al., 2010) 
or (Johnson and van Cauwelaert, 2009). Examples for the formatting of references in the reference list 
can be found in Section 3.2.3.3. EndNote style files are available upon request. 
The following format should be applied to the reference list:  
  no full stops after author initials and no commas between author last name and initial(s);  
  “and” between the penultimate and final author;  
  when the last name starts with „van’, „de’, etc., alphabetise the names according to the 
preposition (e.g. van Cauwelaert comes under „v‟); 
  comma between the end of the author(s) name(s) and the year, and full stop after the year. 
  journal names are preferably written in full and in regular font (no italics, no underline, etc.). 
abbreviated journal names should be avoided;  
  the volume number (where applicable) shall be followed by a comma;  
  the issue or band number shall not be provided unless necessary to identify the publication. If 
included it shall be followed by a comma; 
  a page range shall be inserted (e.g. 42-46), for certain references the total number of pages 
(pp.) are indicated (e.g. 75 pp.), or for single page references the page (p.) where the reference 
is found (e.g. p. 18); 
  full stop at the end of each reference; 
  two or more works by the same author(s) cited at the same time (in alphabetical order), the 
author(s) surname(s) should not be repeated and the years be separated by a comma, from the 
oldest to the most recent (Smith et al., 2007, 2008) or (Johnson, 2006, 2007; Smith et al., 
2007a, b). 
3.2.3.2.  Unpublished studies  
Citations should be derived from file names. EFSA recommends citing an unpublished study such as 
(Appendix xx). These unpublished studies should be listed in an overview table. Examples are given 
in Tables 1-3 of the Appendix B. 
3.2.3.3.  Examples for the formatting of references in the reference list 
Journal articles: 
Icoz I and Stotzky G, 2008. Fate and effects of insect-resistant Bt crops in soil ecosystems. Soil 
Biology and Biochemistry 40, 559-586. 
Unpublished studies carried out by applicants: (if authors‟ names not claimed to be confidential): 
Smith  DK  and  Cramer  JL,  2009.  Updated  bioinformatics  evaluation  of  the  CP4  EPSPS  protein. 
[Applicant name] Technical Report, [Report number], 1-22. 
Appendix 4,  Updated  bioinformatics  evaluation  of  the  CP4  EPSPS  protein.  [Applicant  name] 
Technical Report, [Report number], 1-22. 
 EFSA submission guidance for GM plant applications  
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Book: 
Gregory N and Grandin T, 2007. Animal welfare and the meat market. CABI, Wallingford, UK, 185 
pp. 
Book section: 
Bookers E, Heutinck L, van Reened C and Wolthuis-Fillerup M, 2007. Application of risk assessment 
to animal welfare. In: Animal welfare and the meat market. Eds Gregory NG and Grandin T. 
CABI, Wallingford, UK, 12-21. 
Proceedings/Conference paper: 
Bookers E, Heutinck L, van Reened C and Wolthuis-Fillerup M, 2008. Veal calves generalize their 
response  across  familiar  and  unfamiliar  persons  in  a  repeatable  on-farm  fear  of  humans  test. 
Proceedings of the 4th International Workshop on the Assessment of Animal Welfare at Farm and 
Group Level (WAFL), Ghent, Belgium, 34-35. 
Thesis: 
Lund V, 2002. Ethics and animal welfare in organic animal husbandry: An interdisciplinary approach. 
Thesis (PhD), Swedish University of Agricultural Sciences, Uppsala, Sweden. 79 pp. 
Online document: 
BAS  (Bristol  Aquarists  Society),  online.  Background  information  about  goldfish.  available  at 
http://www.bristol-aquarists.org.uk/goldfish/info/info.htm  
Brosowski J, 1999, online. Animal Diversity Web. Dicentrarchus labrax. University of Michigan, 
available at 
http://animaldiversity.ummz.umich.edu/site/accounts/information/Dicentrarchus_labrax.html 
3.3.  Part III – Cartagena protocol 
Requirements  on  the  structure  and  content  of  Part III  can  be  found  in  Annex I  of  Implementing 
Regulation (EU) No 503/2013. EFSA checks the presence of Part III in a complete application, but 
does not evaluate the content.  
3.4.  Part IV – Labelling 
Requirements on the content of Part IV can be found in Annex I of Implementing Regulation (EU) 
No 503/2013. EFSA checks the presence of Part IV in a complete application, but does not evaluate 
the content.  
Based on the outcome of the risk assessment, EFSA may provide recommendations to the EC for the 
labelling of a GM food or feed product.  
3.5.  Part V – Methods of detection, sampling and identification and reference material 
Part V falls within the remit of the European Union Reference Laboratory (EURL) as referred to in 
Article 32 of Regulation (EC) No 1829/2003. Requirements on the content of Part V can be found in 
Annex I of Implementing Regulation (EU) No 503/2013. Information and requirements of the EURL-
GMFF can be consulted at its website. 
Part V should consist of two files: one summarising the information provided to EURL, including 
information on where the reference material can be accessed; the other documenting the submission of 
the samples, reagents and methods to the EURL-GMFF (see Appendix G).  EFSA submission guidance for GM plant applications  
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3.6.  Part  VI  –  Additional  information  to  be  provided  for  GM  plants  and/or  food/feed 
containing or consisting of GM plants  
Requirements on the content of Part VI can be found in Annex I of Implementing Regulation (EU) 
No 503/2013.  
3.7.  Part VII – Summary of applications 
Requirements  on the structure  and  content  of  Part VII  can  be found  in  Annex I  of  Implementing 
Regulation (EU) No 503/2013.  
Any confidential information should be excluded as this part will be published on the EFSA Register 
of Questions (see Sections 1.4 and 1.6). Please be reminded that during the completeness check phase, 
an updated version should be sent to EFSA together with the revised application. 
3.8.  Part VIII -Administrative documents 
Part VIII of the application shall contain all administrative documents related to the application. The 
list of documents and the standardised naming for the files are listed in Table 3. 
Table 2:   List of administrative documents and their recommended file names 
File name  File content 
01-Letter_to_MS_submission.pdf 
or 
01-Letter_to_EC_submission.pdf 
Cover letter accompanying the submission of the application 
02a-Confidentiality_Data_protection.pdf 
02b-Confidential_name_list.pdf 
Agreement on confidentiality and data protection 
A list of names to be treated as confidential 
03a-Access_letter_event1.pdf 
03b-Access_letter_event2.pdf  
03c…….etc. 
For  GM  plants  containing  stacked  events:  Letter(s)  granting 
consent of access to applications for concerned single events 
(see Section 3.8.1). 
04-CClist.exl  Completeness checklist: filled by the applicant (Appendix A) 
05-DoConformity.pdf  Declaration of  Conformity between  the paper and electronic 
versions of the application  
3.8.1.  Letter “consent of access” 
If an application refers to data already provided in another application previously submitted to EFSA 
(as in the case of applications for stacked events) a letter of “consent of access” from the applicant is 
required. This letter authorises EFSA and all MS CA to use the data previously submitted. Such 
consent letter should be provided independently for each concerned application. 
3.8.2.  Completeness checklist  
The completeness checklist (see Appendix A) for the sections concerning molecular characterisation, 
food and feed risk assessment have been aligned with Implementing Regulation (EU) No 503/2013. 
This  checklist  consists  of  eight  spreadsheets,  corresponding  to  Parts I  to  VIII  of  a  GM  plant 
application. This checklist, filled out by applicants, is used by EFSA during the completeness check 
phase to ensure that (i) GM plant applications follow the required structure, and  (ii) all required 
information and documents are provided. 
4.  Applications for GM plants containing stacked events  
In accordance with Implementing Regulation (EU) No 503/2013, the risk assessment of each single 
transformation  event  in  GM  plants  containing  events  stacked  by  conventional  crossing  is  a  pre-
requisite for the risk assessment of the stack and when submitting applications, the applicant shall 
provide  a  risk  assessment  of  each  single  transformation  event  or  refer  to  already  submitted EFSA submission guidance for GM plant applications  
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applications. As clarified by the EC
11, single events should be subject to separate and stand-alone 
applications. Such references must precise in detailing the section, page number, appendix, figure, 
name of the relevant reports and information. 
The evaluation of applications for GM plants containing stacked events builds on the knowledge 
acquired during the risk assessment of all the involved single events. Therefore, EFSA will start the 
risk  assessment  of  an  application  for  GM  plants  containing  stacked  events  only  after  the  risk 
assessment of the respective single events is completed. In line with Implementing Regulation (EU) 
No 503/2013,  applications  for  GM  segregating  crops  should  include  all  sub-combinations 
independently of their origin and not yet authorised. 
5.  Applications for renewal authorisations  
All applications submitted under Articles 5, 11, 17 and 23 of Regulation (EC) No 1829/2003 should 
follow the structure specified in section 2.1 of this submission guidance. It is important to note that the 
EFSA  GMO  Panel  is  preparing  Guidance  for  renewal  authorisations  of  existing  GMO  products 
submitted under Articles 11 and 23 of Regulation (EC) No 1829/2003. 
USEFUL WEBSITES 
EFSA Register of Questions: http://registerofquestions.efsa.europa.eu/roqFrontend.  
Community Reference Laboratory for GM food and feed: http://gmo-crl.jrc.ec.europa.eu 
EU authorisation procedure for GMOs: http://ec.europa.eu/food/plant/gmo/authorisation/index_en.htm 
EU register of GM food and feed: http://ec.europa.eu/food/dyna/gm_register/index_en.cfm 
EFSA GMO Extranet: https://sciencenet.efsa.europa.eu/portal/server.pt 
EFSA Journal: http://www.efsa.europa.eu/en/efsajournal.htm 
Minutes of EFSA GMO Panel plenary meetings: http://www.efsa.europa.eu/en/gmo/gmomeetings.htm  
Minutes of EFSA GMO Panel WG meetings: http://www.efsa.europa.eu/en/gmo/gmowgs.htm 
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APPENDICES 
Appendices A, C, D, E, F described below are available in electronic format on EFSA website. 
A.  COMPLETENESS CHECKLIST 
The completeness checklist contains eight spreadsheets, corresponding to each of the eight parts of an 
application package. The completed document should be submitted in XLS format and included in 
Part VIII. 
B.  EXEMPLAR FIGURES AND TABLES FOR PART II 
Appendix B contains examples of figures and tables to present data on molecular characterisation and 
food and feed risk assessment. These figures and tables should not be viewed as precise templates. 
Other formats are accepted, provided that the aim is achieved. They should be included in Part II. 
C.  SCHEMATIC SUMMARY OF FIELD TRIALS 
Appendix C is a schematic summary for each field trial conducted to support the comparative analysis 
of agronomic and phenotypic characteristics. They should be included in Part II. 
D.  SCHEMATIC  SUMMARY  OF  INSECT  RESISTANCE  MANAGEMENT-RELATED 
INFORMATION  
Appendix D is requested for GM plant applications covering GM plants expressing insect resistance 
traits for cultivation in the EU. The applicant should include it in the subfolder ERA_Appendices D to 
F. 
E.  SCHEMATIC SUMMARY OF NTO STUDIES 
Appendix E consists of four parts, each requesting specific information on the NTO studies submitted 
as  part  of  the  GM  plant  application.  The  applicant  should  include  it  in  the  subfolder 
ERA_Appendices D to F. 
  Part 1: Overview of NTO studies performed or commissioned by the applicant; 
  Part 2: Overview of NTO studies published in peer-reviewed journals and used by the 
applicant in support of NTO risk assessment; 
  Part 3: Summary of laboratory studies performed or commissioned by the applicant to support 
the NTO risk assessment; 
  Part 4: Summary of field studies performed or commissioned by the applicant to support the 
NTO risk assessment. 
F.   SCHEMATIC SUMMARY OF STATISTICAL DESIGN AND ANALYSIS FOR EACH ERA-
RELATED STUDY 
For each experimental study submitted in support of the ERA, the applicant should compile a separate 
Appendix F. All completed Appendices should be included in the subfolder ERA_Appendices D to F. 
G.  PROOF OF ACKNOWLEDGEMENT OF RECEPTION BY EURL-GMFF 
Appendix G contains an “Acknowledgement of reception of samples, reagents and methods” used by 
EURL-GMFF. A copy of such document for a specific GM event should be included in Part V. EFSA submission guidance for GM plant applications  
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ABBREVIATIONS 
CI:    Confidential Information 
CA:     National Competent Authority 
CC:    Completeness Check 
CD-ROM:  Compact Disk - Read Only Memory 
EURL-GMFF:  European Union Reference Laboratory for GM Food and Feed 
EC:    European Commission 
EU:    European Union 
EFSA:    European Food Safety Authority 
ENV:    Environment 
ERA:    Environmental Risk Assessment 
FF:    Food and Feed 
GM:    Genetically Modified 
GMO:    Genetically Modified Organisms 
MC:    Molecular Characterisation 
MS:    Member State 
MS CA   National Competent Authority of a Member State  
non-CI:   Non-Confidential Information 
WG:    Working Group General requirements
General requirements as outlined in the EFSA submission guidance 
(version 3) for GM plants
Yes, 
provided 
Not applicable EFSA agrees 
EFSA comments/questions 
to applicants
Part I - Genernal information
Part II Scientific information
Part III – Cartagena Protocol
Part IV – Labelling proposal
Part V – Detection and validation methods
Part VI – Additional information 
Part VII – Summary 
Part VIII – Administrative documents
In case of a stacked application, letter(s) of consent of access for all
single events
Statement of conformity between electronic and paper copy   
1 electronic copy
1 paper copy
Declaration of Conformity between the paper and electronic versions
of the application
Passwords of CDs or files (if applicable) are provided
CD(s) are labelled as described in section 2.4.1of the submission 
guidance
DNA sequence information in Gen Bank format including annotation 
information
File size smaller than 25 MB
For EFSA use
Submission data package
File format, size and name
A GM plant applicant consists of the following eight partsGeneral requirements
Files are word searchable
All files named as described in section 2.1 of the submission guidance
Files names shorter than 40 characters
At submission, Confidential (CI) from non-confidential information 
(non-CI) are stored on separate CDs 
At submission, CI and non-CI are stored on the same CD, but 
organised in separate folders. 
Files containing confidential information contain "CI" in the file names 
(e.g. "Appendix_5_CI.pdf")
main text does NOT contain CI
If authors' names are claimed as confidential, they are not included in 
the citation
A list, containing all the names to be treated as confidential 
information, is provided to EFSA 
References are listed in alphabetical order at the end of Part II
Citations of published studies in line with the formatting requirements 
of the Submission guidance section 3.2.3. 
Citations of unpublished studies in line with the formatting 
requirements of the Submission guidance section 3.2.3.
Citation, reference and file names are consistent throughout all 
documentation  
Citations and References
Confidential informationGeneral requirements
Comments (up to 500 characters)
Please insert your comments herePart I - General Info
Part I - General information
Yes, 
provided 
Not applicable 
(justification 
provided in Part I)
EFSA agrees 
EFSA 
comments/questions 
to applicants
1.    Name and address of the applicant (company or institute) 
2.    Name, qualification and experience of the responsible 
scientist(s) and contact details of the responsible person for all 
dealings with EFSA
3.    Designation and specification of the GM plant and its products
4.    Scope of the application is clearly indicated
    Where an application is limited to either food or feed use, it shall 
contain a verifiable justification explaining why the authorisation shall 
not cover both uses in accordance with Article 27 of Regulation (EC) 
No 1829/2003
    For GM plants containing stacked transformation events 
(segregating crops), the list of all sub-combinations not yet 
authorised is included in the scope of the application 
5.    Unique identifier: : a proposal for a unique identifier for the GM 
plant developed in accordance with Regulation (EC) No 65/2004
6.    Where applicable, a detailed description of the method of 
production and manufacturing. 
     for example, a detailed description of specific methods of 
production of food or feed which would be due to the nature of the 
genetic modification or which would lead to food or feed with specific 
characteristics
7.    Where appropriate, the conditions for the placing on the market 
of the genetically modified food(s) or feed(s), including specific 
conditions for use and handling
8.   Where applicable, the status of the food or feed or of related 
substances under other provisions of Union law.
For EFSA usePart I - General Info
     Additional authorisation requirements provided for in Union law, 
related to the placing on the market of the food or feed, or applicable 
‘maximum residue level’ (MRL) where the food or feed is likely to 
contain residues of plant protection products.
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
Part II - Scientific Information
Yes, 
provided 
Not applicable EFSA agrees 
EFSA comments/questions to 
applicants
Applicants should filled out the completeness checklist when preparing a GM 
plant application.                                                                          Only one box 
should be checked in each row.                                                                       
Information 
provided 
If this box is checked, a 
justification should be 
included in the main 
text of Part II
 
Information on the study protocols and the results obtained from 
all studies is comprehensive and include the raw data in an 
electronic format, suitable for carrying out statistical or other 
analysis.  
(a) requirements of Directive 2004/10/EC; or  
(b) ‘OECD Principles on Good Laboratory Practice’ (GLP), if 
carried out outside the Union.  
Evidence to demonstrate such compliance is provided.  
(a) comply with the principles of Good Laboratory Practice 
(GLP) laid down in Directive 2004/10/EC; or  
(b) be conducted by organisations accredited under the relevant 
ISO standard.
 
Overview table of all Appendices and key references is provided 
(for example see Table 1 in Appendix B of the Submission 
Guidance)  
Study overview table (for example see Table 2 in Appendix B of 
the Submission Guidance)  
Considerations for Part II as outlined in the EFSA Submission Guidance
For EFSA use only
Specific considerations as outlined in Annex II of the Implementing Regulation (EU) No 
503/2013
Using the filled-out completeness checklist, EFSA verifies that all 
information is present in Part II; the information provided is in line 
with the Implementing Regulation (EU) No 503/2013; and the data 
presentation is in line with the EFSA submission guidance.
Specific requirements for the performance of studies for applications submitted under 
Articles 5(3) and 17(3), as outlined in the Implementing Regulation (EU) No 503/2013
Insertion of marker genes and other nucleic acid(s) sequences not essential to achieve the 
desired trait
Toxicological studies shall be conducted in facilities which comply with the
Studies, other than toxicological studies, shallPart II - Sci Info
Clear indication if the GM plant contains antibiotic resistance 
marker gene(s) or other non essential sequences
The GM plant contains stacked transformation events obtained 
by conventional crossing
 -  applications on single events are clearly referrenced in this 
application
 - for segregating crops, this application includes all sub-
combinations independently of their origin which have not yet 
been authorised
 - this application contains a scientific rationale justifying that 
there is no need to provide experimental data for the concerned 
sub-combinations or, in the absence of such scientific rationale, 
contains the experimental data
 - for non-segregating crops, this application covers only the 
combination which is to be placed on the market
The GM plant contains transformation events that are combined 
by other means such as co- and retransformation
 
 
(a) Complete name: 
(i) family name
(ii) genus
(iii) species
(iv) subspecies
(v) cultivar/breeding line or strain
(vi) common name
(b) Geographical distribution and cultivation of the plant within 
the Union 
(c) Information on the recipient or parental plants relevant to 
their safety, including any known toxicity and/or allergenicity 
A. Hazard identification and characterisation
1. Information relating to the recipient or (where appropriate) parental plants
Scientific requirements for the risk assessment of GM food and feed as outlined in Annex II of the Implementing Regulation (EU) No 503/2013
Risk assessment of genetically modified food and feed containing stacked transformation eventsPart II - Sci Info
(d) Data on the past and present use of the recipient organism. 
This information should include:
 - the history of safe use for consumption as food and/or feed
 - how the plant is typically cultivated, transported and stored
 - whether special processing is required to make the plant safe 
to eat
 - the description of the normal role of the plant in the diet (e.g. 
which part of the plant is used as a food source, whether its 
consumption is important in particular subgroups of the 
population, what important macro- or micro-nutrients it 
contributes to the diet)
 – mode(s) of reproduction
 – specific factors affecting reproduction (if any) 
 – generation time
 – ability to form structures for survival or dormancy
 – specific factors, if any, affecting survivability
 – ways and extent of dissemination (to include, for example, an 
estimation of how viable pollen and/or seed declines with 
distance)
 – special factors affecting dissemination, if any
(ii) Sexual compatibility with other cultivated or wild plant species
(iii) Survivability
(iv) Dissemination
(v) Geographical distribution within the Union of the sexually compatible species
(vi) Where a plant species is not grown in the Union, a description of the natural habitat of the 
plant, including information on natural predators, parasites, competitors and symbionts
Additional information relating to the recipient or parental plants required for the environmental 
safety aspects
(i) Information concerning reproductionPart II - Sci Info
 
 
(a) method of genetic transformation including relevant 
references
(b) the recipient plant material
(c) the species and strain of Agrobacterium and other microbes
(d) helper plasmids
(e) source of carrier nucleic acids
(a) physical map of the functional elements and
 - physical map of other plasmid/vector components
 - relevant information needed for the interpretation of the 
molecular analyses
 - indication of the region intended for insertion
(b)  a table identifying: 
 - each component of the plasmid/vector
 - its size
 - its origin  
 - its intended function
 -  taxonomic classification;
 - history of use regarding food and feed safety
1.2 Molecular Characterisation
1.2.1 Information relating to the genetic modification
1.2.1.1 Description of the methods used for the genetic modification
1.2.1.2 Nature and source of vector used
Information on the donor organism(s);  for each donor organism this shall comprise of: 
1.2.1.3 Source of nucleic acid(s) used for transformation, size and intended function of 
each constituent fragment of the region intended for insertion
(vii) Other potential interactions of the genetically modified plant with organisms in the ecosystem 
where it is usually grown, or used elsewhere, including information on toxic effects on humans, 
animals and other organisms.Part II - Sci Info
Information on the nucleic acid(s) sequence(s) intended to be 
inserted
Information regarding the function of the nucleic acid region(s) 
(a) the complete sequence of the nucleic acid(s) intended to be 
inserted;including
 - information on any deliberate alteration(s) to the 
corresponding sequence(s) in the donor organism(s)
(b) the history of safe use of the gene product(s) arising from 
the regions intended for insertion
(c) data on the possible relationship of the gene products with 
known toxins, anti-nutrients and allergens
Discussion whether the nature of the donor organism(s) or the 
nucleic acid sequence(s) may trigger any safety issue
Description of the introduced trait(s), of the resulting changes 
on phenotype and metabolism of the plant
If the trait is herbicide tolerance, information on the mode of 
action of the active substance and its metabolism in the plant.
(a) copy number of all detectable inserts, both complete and 
partial, and
 the size of all detectable inserts, both complete and partial; this 
is typically determined by Southern analysis
1.2.2.2  Information on the sequences actually inserted/deleted
1.2.2.1 General description of the trait(s) and characteristics which have been introduced 
or modified
1.2.2 Information relating to the genetically modified plantPart II - Sci Info
 - probe/restriction enzyme combinations shall provide complete 
coverage of sequences that could be inserted into the GM plant, 
such as any parts of the plasmid/vector or any carrier or foreign 
nucleic acid(s) remaining in the GM plant
 - analyses shall span the entire transgenic locus/loci as well as 
the flanking sequences and
 - include appropriate controls 
(b) the organisation of the inserted genetic material at each 
insertion site 
 - sequence of the inserted genetic material at each insertion 
site in a standardised electronic format
 - identifying changes in the inserted sequences compared to 
the sequence intended for insertion
c) in the case of deletion(s), size and function of the deleted 
region(s)
d) sub-cellular location(s) of insert(s) and methods for its/their 
determination
e) sequence information in a standardised electronic format for 
5’  flanking regions at each insertion site
 - sequence information in a standardised electronic format for 
3’  flanking regions at each insertion site
 - identification of interruptions of known genes
 - bioinformatic analyses using up-to-date databases to perform 
both intraspecies and interspecies similarity searches
In case of stacked events: safety assessment of potential 
interactions between any unintended modification at each 
insertion site
f) ORFs created as a result of the genetic modification either at 
the junction sites with genomic DNA or due to internal 
rearrangements of the insert(s).
 - ORFs analysed between stop codons, not limiting their 
lengths
 - Bioinformatic analyses to investigate possible similarities 
with known toxins or allergens using up-to-date databases
If Southern analyses is used: Part II - Sci Info
 - The characteristics and versions of the databases 
 Bioinformatic overview table (for example see Table 3 in 
Appendix B)
 Further analyses (such as transcription analysis), if needed 
Overview table - Field trial for protein expression analyses (for 
example see Table 4 in Appendix B)
a) The method(s) used for expression analysis 
 - the performance characteristics
b) Information on developmental expression of the insert during 
the life cycle of the plant
c) Parts of the plant where the insert/modified sequences are 
expressed;
d) Characterise potential unintended expression of new ORFs 
identified under point 1.2.2.2(f) which raise a safety concern
e) Protein expression data obtained from field trials and related 
to the conditions in which the crop is grown
 - including raw data
 - data on expression levels from those parts of the plant used 
for food and feed purposes
 - expression of target genes in other parts of the plant when 
tissue-specific promoters are used and when relevant for the 
safety assessment
 - protein expression data from three growing sites or from one 
site over three seasons
Depending on the nature of the insert specific RNA(s) or 
metabolite(s) shall be analysed
For silencing approaches by RNAi expression, potential ‘off 
target’ genes should be searched by in silico analysis 
 - assess if the genetic modification affects the expression of 
other genes which raise safety concerns
To investigate intended and unintended changes at the protein, RNA and/or metabolite levels; 
Following elements are provided: 
1.2.2.3 Information on the expression of the insert(s)Part II - Sci Info
 - provide expression data to assess potential interactions 
between the events, which may raise any additional safety 
concerns over protein and trait expression compared to the 
single transformation events
 - the comparison carried out with data obtained from plants 
grown in the same field trial
 - on a case-by-case basis, and where concerns arise, 
additional information is provided.
(a) Demonstrate the genetic stability of the transgenic locus(i) 
using appropriate molecular approaches,and
 demonstrate the phenotypic stability of the introduced trait(s), 
and
 demonstrate inheritance pattern(s) of the introduced trait(s)
 - demonstrate stability over multiple (normally five - first and 
last generation is sufficient) generations or vegetative cycles
 - source of the material used for the analysis is specified
 - data analysed using appropriate statistical methods
 establish that each transformation event in the stacked event 
has the same molecular properties as the single transformation 
events
 establish that each transformation event in the stacked event 
has the same characteristics as the single transformation 
events
 compare plant materials representative of those designed for 
commercial production with original transformation events, 
including:
 - sequence comparison of inserts obtained from the single 
events and the stacked events
 - sequence comparison of the flanking regions obtained from 
the single events and the stacked events
 provide adequate justification for the plant materials used
f) With regards to stacked events by conventional crossing:
(b) In case of stacked events:
1.2.2.4 Genetic stability of the insert and phenotypic stability of the GM plantPart II - Sci Info
Assess the probability of horizontal gene transfer and any 
potential associated risk when intact and functional nucleic 
acid(s) remains in the genetically modified food and feed: 
 - from the product to humans
 - from the product to animals
 - from the product to micro-organisms
 Conclusion on the structure of the insert
 Conclusion on the expression of the insert
 Conclusion on the stability of intended trait(s)
 Indicate whether the molecular characterisation of the genetic 
modification(s) raises safety concerns with regard to the 
interruption of endogenous genes or regulatory sequences.
 Identify whether the genetic modification(s) raise(s) any issues 
regarding the potential for producing proteins/substances other 
than those intended and in particular new toxins or allergens
 Identify potential unintended changes that shall be addressed 
in the relevant complementary parts of the safety assessment
 
A breeding scheme (pedigree) in relation to the GM plant, the 
conventional counterpart and, where appropriate, additional 
comparator(s) (for example see Appendix B) 
 - together with an adequate justification of their selection
1.3.1 Choice of the conventional counterpart and additional comparators
1.2.2.5. Potential risk associated with horizontal gene transfer
1.2.3 Conclusions of the molecular characterisation
1.3. Comparative analysis
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
 - qualitative and quantitative data to support the history of safe 
use of the conventional counterpart 
 - conventional counterpart shall, in principle, be the near-
isogenic variety used to generate the transgenic line
 - additional comparator(s)
 - conventional counterpart shall have a genetic background 
comparable to the GM plant. 
 - When using back-crossing, a conventional counterpart with a 
genetic background that is as close as possible to the GM plant 
is selected.
 - (optional) an additional comparator having a closer genetic 
background to the GM plant than the conventional counterpart 
(such as a negative segregant)
 - the GM plant exposed to the intended herbicide
 - the conventional counterpart treated with conventional 
herbicide management regimes
 - the GM plant treated with the same conventional herbicide 
management regimes
 In case that it is not possible to use a conventional counterpart 
with a genetic background as close to the GM plant as with 
conventional counterpart normally used for single 
transformation events, reasoned justification on the choice of 
the conventional counterpart and assess its limitations for the 
risk assessment, are provided.
Single parental GM lines or GM lines containing a sub-
combination of the stacked transformation events for which an 
application has been submitted or negative segregants derived 
from these genetically modified lines may also be included as 
additional comparators.
For crops that reproduce sexually
For vegetatively propagated crops
For herbicide tolerant genetically modified plants
For stacked transforamtion eventsPart II - Sci Info
 - if so, detailed information justifying the choice of additional 
comparators is provided.
Field trial(s) are performed for the production of material for the 
comparative analysis
 - all test materials are randomised to plots within a single field 
at each site, in a completely randomised or randomised block 
experimental design
 - the choice of non-GM reference varieties is appropriate for 
the chosen sites, and is justified explicitly.
 - at least six different non-GM reference varieties are used over 
the entire set of field trials
 - the different sites selected for the field trials reflect the 
different meteorological and agronomic conditions under which 
the crop is to be grown; the choice is explicitly justified.
 - a minimum of eight sites
 - the field trials may be conducted in a single year, or spread 
over multiple years.
 - if the sites cover a restricted range of growing conditions, the 
field trials are replicated over more than one year.
The field trials are adequately described, giving information on 
important parameters such as management of the field before 
sowing, date of sowing, soil type, herbicide use, climatic and 
other cultivation/environmental conditions during growth and 
time of harvest, as well as the conditions during storage of the 
harvested material.
 - the test materials consiste of GM plants, conventional 
counterpart and, where appropriate, additional comparator(s) 
 - the test materials are identical between replicates
Each site shall meet the following requirements:
Each field trial shall meet the following requirements:
1.3.2 Experimental design and statistical analysis of data from field trials for comparative 
analysis
1.3.2.1 Description of the protocols for the experimental design
Specific protocols for experimental design Part II - Sci Info
 - unless explicitly justified for not doing so, at least three 
appropriate non-GM reference varieties  
 - non-GM reference varieties have a known history of safe use
 -  non-GM reference varieties are identical between replicates
 - the number of replications is four or more
 - if only two appropriate reference varieties are available at a 
particular site, then the replication is six at that site;
  - if only one appropriate reference variety is available at a 
particular site, then the replication is eight at that site.
 (i) the conventional counterpart and, where appropriate, 
additional comparator(s) always occur together with the GM 
plant in the same block;
 (ii) all the different GM plants and their comparator(s) and all 
the non-GM reference varieties used for the equivalence test 
are fully randomized within each block.
 (i) the conventional counterpart always occurs together with its 
particular GM plant in the same block;
 (ii) all of the non-GM reference varieties appear in each of the 
incomplete blocks and are fully randomised with the plants and 
their comparator(s).
Analysis of data is presented in a clear format, using 
standardised scientific units.
The raw data and the programming code used for the statistical 
analysis are given in an editable form.
The natural scale or another scale has been used for the 
endpoint response variables.
When the GM plant is tested together with other GM plants of the same crop species to produce 
material for the comparative assessment, the following two conditions are met:
If the number of plots per block required for such a field trial were to exceed 16, then a partially 
balanced incomplete block design may be used, to reduce the number of plots per block, by 
excluding some of the GM plants and their appropriate comparator(s) from each block. This is 
done, provided that the following two conditions are met:
1.3.2.2 Statistical analysisPart II - Sci Info
When data transformation is applied, any difference between 
the GM material and any other test material are interpreted as a 
ratio on the natural scale. 
In testing for difference, the null hypothesis is that there is no 
difference between the GMO and its conventional counterpart
 - Where additional comparator(s) are used, a test of difference 
is carried out between the GM plant and each of the additional 
comparator(s)
In testing for equivalence, the null hypothesis is that the 
difference between the GMO and the set of reference varieties 
is at least as great as a specified minimum size 
 - Rejection of the null hypothesis is required in order to 
conclude that the GMO and the set of reference varieties are 
unambiguously equivalent for the endpoint considered
 - The equivalence limits used for the test of equivalence 
represent appropriately the range of natural variation expected 
for reference varieties with a history of safe use
The total variability of each endpoint observed in the field trials 
are estimated and partitioned using appropriate statistical 
models in order to derive two sets of confidence limits and to 
set a lower and upper equivalence limit based on the variability 
observed among the non-GM reference varieties, one to be 
used in the test of difference; the other and the equivalent limits 
to be used in the test of equivalence.
A linear mixed statistical models is used to calculate both sets 
of confidence limits
 - the random factors for model 1 are, but not necessarily be 
restricted to, those representing the variation: (i) between the 
test materials; (ii) in the interaction between the test materials 
and the indicator variable I; (iii) between sites; and (iv) between 
blocks within sites.
 - Model 2 is identical to model 1 except that the random factor 
representing the interaction between the test materials and the 
indicator variable I is omitted
For each endpoint, a test of difference and a test of equivalence are carried outPart II - Sci Info
 - The fixed factor for both models have as many levels as there 
are test materials and represent the contrasts between the 
means of the test materials. 
 - The set of non-GM reference varieties is considered as a 
single level of the fixed factor. 
 - For the difference test, the component of the fixed factor of 
interest is the single degree-of-freedom contrast between the 
GM plant and its conventional counterpart.
 - For the equivalence test, the component of the fixed factor of 
interest is the single degree-of-freedom contrast between the 
GM plant and the set of non-GM reference varieties.
 - Both the difference test and the equivalence test are 
implemented using the correspondence between hypothesis 
testing and the construction of confidence limits.
 - In equivalence testing, the approach used shall follow the two 
one-sided tests (TOST) methodology by rejecting the null 
hypothesis of non-equivalence when the both confidence limits 
fall between the equivalence limits. 
 - The choice of 90% confidence limits corresponds to the 
customary 95% level for statistical testing of equivalence.
 - The results of the difference and equivalence tests are 
represented visually for all the endpoints simultaneously, on a 
single graph or a few graphs.
 - The graph(s) show the line of zero difference between the GM 
material and its conventional counterpart and, for each 
endpoint: the lower and upper adjusted equivalence limits; the 
mean difference between the genetically modified material and 
its conventional counterpart; and the confidence limits for this 
difference.
 - The line of zero difference on the logarithmic scale 
corresponds to a multiplicative factor of unity on the natural 
scale.
 -  The horizontal axis is labelled with values that specify the 
change on the natural scale.
 - In the case of logarithmic transformation, changes of 2x and 
½x will appear equally spaced on either side of the line of zero 
difference.Part II - Sci Info
 - When, in addition to the conventional counterpart, another 
test material is used as comparator, the mean difference 
between the GM material and that comparator, its confidence 
limits and its adjusted equivalence limits shall be displayed on 
the graph(s) , for all such additional comparators, by referring 
this to the same zero baseline as defined by the conventional 
counterpart.
 (a) the assumptions underlying the analysis
 (b) full specification of the mixed models chosen, including 
fixed and random effects
 (c)  results of any test of interaction between the test materials 
and sites
 (d) fixed effects, together with the appropriate estimated 
residual variation with which they are compared, and variance 
components for the random factors;
 (e) estimated degrees of freedom
 (f) any other relevant statistics
A. Regarding test of difference, each outcome from the graph is 
categorised and the respective appropriate conclusion is drawn
B. Regarding test of equivalence, each outcome from the graph 
is categorised, and the respective appropriate conclusion is 
drawn.
Despite the expected proportion of spurious significant 
differences, report and discuss all significant differences 
observed between the GMcrop, its conventional counterpart 
and, where applicable, any other test material, focusing on their 
biological relevance.
A discussion on the likely impact of other growing conditions not 
tested in the field trial is provided
In the case of significant difference and/or lack of equivalence 
for any particular endpoint, further statistical analysis is carried 
out to assess whether there are interactions between any of the 
test materials and site. 
For reporting, full details are given for each endpoint analysed, listingPart II - Sci Info
 - Whatever approach is adopted, details are given, for each 
endpoint analysed, listing:
 (a) the assumptions underlying the analysis,
 and, when appropriate: (b) degrees of freedom,
(c) the estimated residual variation for each source of variation, 
and variance components,
(d) any other relevant statistics. 
 Discussion of these additional analyses, which are intended to 
aid the interpretation of any significant differences found and to 
study potential interactions between test materials and other 
factors.
The material to be used for the comparative assessment are 
selected while taking into account the uses of the GM plant and 
the nature of the genetic modification. 
In the case of herbicide tolerant GM plants, three test materials 
are used: the GM plant exposed to the intended herbicide; the 
conventional counterpart treated with conventional herbicide 
management regimes; and the GM plant treated with the same 
conventional herbicide management regimes. 
Analysis is carried out on the raw agricultural commodity.
Additional analysis of processed products are conducted, where 
appropriate, and on a case-by-case basis
The sampling, analysis and preparation of the tested material 
are carried out according to appropriate quality standards.
The quality standards applied are referenced.
The specific analyses are tailored to the plant species, and 
include a detailed assessment appropriate to the intended effect 
of the genetic modification, the considered nutritional value and 
use of the plant.
1.3.4 Comparative analysis of composition
 Compounds selection refers to OECD consensus documents, and includes at least 
1.3.3 Selection of material and compounds for analysisPart II - Sci Info
 - proximates (including moisture and total ash)
 - key macro- and micro-nutrients
particular attention paid to key nutrients such as proteins, 
carbohydrates, lipids/fats, fibre, vitamins and minerals
 vitamins and minerals which are present at nutritionally 
significant levels and/or which make nutritionally significant 
contributions to the diet
a fatty acid profile is included for oil-rich plants (main 
individual saturated, mono-unsaturated and poly-unsaturated 
fatty acids)
an amino acid profile (individual protein amino acids and main 
non-protein amino acids) for plants used as an important 
protein source
 - anti-nutritional compounds
The concentrations of anti-nutritional compounds are 
assessed according to plant species and the proposed use of 
the food and feed product
 - key toxins inherently present in the recipient plant which may 
adversely affect human/animal health depending on their toxic 
potency and levels
The concentrations of key toxins are assessed according to 
plant species and the proposed use of the food and feed 
product
 - already identified allergens
 - other secondary plant metabolites characteristic for specific 
crop plant species
 - analysis of plant cell wall components for the vegetative parts 
of plants used for feed purposes
The characteristics of the introduced trait triggers further 
analysis of specific compounds including metabolites of 
potentially modified metabolic pathways. 
If so, inclusion of compounds other than the key nutrients, key 
toxins, anti-nutrients and allergens identified by the OECD 
consensus documents and justify the selection of these 
compoundsPart II - Sci Info
The protocols of these field trials follow the specifications set 
out in Section 1.3.2.
A comparison between the GM plant and its conventional 
counterpart
 - identification of unintended effects resulting from the genetic 
modification
 - address plant biology and agronomic traits, including 
common breeding parameters (such as yield, plant 
morphology, flowering time, day degrees to maturity, duration 
of pollen viability, response to plant pathogens and insect 
pests, sensitivity to abiotic stress)
Phenotypic characteristics and agronomic properties of stacked 
transformation events are assessed in field trials
Where appropriate, additional information on agronomic traits of 
the stacked transformation events from additional field trials
Description of the different processing technologies in sufficient 
detail, paying special attention to the steps which may lead to 
significant changes in the product content, quality or purity.
Assessment of whether or not the processing and/or preserving 
technologies applied are likely to modify the characteristics of 
GM end products compared with their respective conventional 
counterpart.
When genetic modification targets metabolic pathways resulting in changes in the concentration of 
non-protein substances or in new metabolites (such as in nutritionally enhanced foods), processed 
products are assessed. On a case-by-case basis, additional experimental data shall be submitted.
1.3.5 Comparative analysis of agronomic and phenotypic characteristics
1.3.6 Effects of processing
Where transformation events are stacked by conventional crossing, there may also be changes to 
agronomic and phenotypic characteristics.Part II - Sci Info
Scientific rationale for the risk assessment of these products.
Depending on the product, information on the composition, level 
of undesirable substances, nutritional value and metabolism, as 
well as on the intended use
Depending on the nature of the newly expressed protein(s), 
assessment on the extent to which the processing steps lead to 
the concentration or to the elimination, denaturation and/or 
degradation of these protein(s) in the final product
(a) whether agronomic and phenotypic characteristics of the 
GM plant are, except for the introduced trait(s), different to the 
characteristics of its conventional counterpart and/or equivalent 
to the reference varieties, taking into account natural variation;
(b) whether compositional characteristics of the GM food and 
feed are, taking into account natural variation, different to the 
characteristics of its conventional counterpart and/or equivalent 
to the reference varieties, except for the introduced trait(s);
(c) characteristics for which the GM plant or the GM food and 
feed are different to the characteristics of its conventional 
counterpart and/or not equivalent to the reference varieties 
taking into account natural variation, which need further 
investigation;
(d) whether, in the case of transformation events stacked by 
conventional crossing, there are indications of interactions 
between the combined transformation events.
 
The conclusion of the comparative analysis clearly states:
Comments (up to 500 characters)
Please insert your comments here
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 - determination of the primary structure
 - molecular weight
 - studies on post-translational modifications 
 - a description of its function
 - evaluation of potential interaction with other plant constituents
 - temperature and pH range for optimum activity
 - substrate specificity
 - possible reaction products
 - to proteins known to cause adverse effects, such as toxic 
proteins
 - to proteins exerting a normal metabolic or structural function 
The database(s) and the methodology used to carry out the 
search are specified
 - influences of temperature and pH changes
 - potential modification(s) of the proteins (such as denaturation) 
and/or production of stable protein fragments generated through 
such treatments
 - Stable breakdown products are characterised and evaluated 
with regard to the potential to cause adverse health effects 
linked to their biological activity
 Evaluation of all newly expressed proteins shall include:
In the case of newly expressed enzymes, information on the enzyme activities, including
(b) An up-to-date search for homology
1.4 Toxicological assessment
(c) A description of the stability of the protein under relevant processing and storage conditions 
and the expected treatment of the food and feed.
(d) Data concerning the resistance of the newly expressed protein to proteolytic enzymes (such as 
pepsin).
1.4.1 Testing of newly expressed proteins
(a) A molecular and biochemical characterisation of the newly expressed protein, includingPart II - Sci Info
If so, to provide necessary information regarding the history of 
safe use of the proteins
The tested protein is the one expressed in the GM plant
 by comparisons of the molecular weight, amino acid 
sequence, post-translational modification, immunological 
reactivity and, 
by, in the case of enzymes, the enzymatic activity
In case of differences between the plant expressed protein and 
its microbial substitute, the significance of these differences for 
the safety studies are evaluated.
Studies with combined administration of proteins are performed.
When appropriate depending on the outcome of the 28-day 
toxicity study, further targeted investigations are provided.
 - evaluation of their toxic potency
 - evaluation of the need of toxicological testing as well as 
 - determination of their concentration in GM food and feed
As regards proteins expressed in the GM plant, in the case where the history of safe use for 
consumption as food and/or feed of both the plant and the newly expressed proteins is duly 
documented, specific toxicity testing is not required. 
As regards proteins expressed in the GM plant, where specific testing is required
If, due to the lack of sufficient amount of test materials from the plant, a protein produced by micro-
organisms is used, the structural, biochemical and functional equivalence of this microbial 
substitute to the newly expressed plant protein is demonstrated.
When the genetic modification results in the expression of two or more proteins in the genetically 
modified plant and when, based on scientific knowledge, a possibility of synergistic or antagonistic 
interactions of safety concerns is identified
Risk assessment of identified new constituents other than proteins. This shall include, on a case-
by-case basis:
(e) A repeated dose 28-day oral toxicity study with the newly expressed protein in rodents.
1.4.2 Testing of new constituents other than proteinsPart II - Sci Info
 - on metabolism/toxicokinetics
 - sub-chronic toxicity
 - genotoxicity
 - chronic toxicity
 - carcinogenicity
 - reproduction and developmental toxicity
 - any other appropriate type of study
 
A detailed risk assessment based on the knowledge of the 
physiological function and/or toxic properties of the altered 
levels of food and feed constituents such as macro- and 
micronutrients, anti-nutrients, and natural toxins as well as other 
secondary plant metabolites,
to determine if, and to what extent, the need of additional 
toxicological tests with whole GM food/feed on selected food 
and feed constituents.
A 90-day feeding study with whole food and feed in rodents is 
performed for a single transformation event or for stacked 
transformation events which are not obtained by conventional 
crossing.
1.4.3 Information on altered levels of food and feed constituents
1.4.4 Testing of the whole genetically modified food and feed 
To establish the safety of new constituents having no history of safe use for consumption in food 
and feed, the applicant shall provide information analogous to that described in the EFSA 
Guidance for submissions for food additive evaluations of 16 August 2012 and Commission 
Regulation (EC) No 429/2008 on detailed rules for the implementation of Regulation (EC) No 
1831/2003 as regards the preparation and the presentation of applications and the assessment 
and the authorisation of feed additives. This includes the submission of information on a core set 
of studies such as
This section applies only in the case where the intended or unintended effect of the genetic 
modification would result in an alteration of the levels of food and feed constituents beyond the 
natural variation.
1.4.4.1 90-day feeding study in rodents with whole GM food/feed
GM plant containing stacked transformation events obtained by conventional crossingPart II - Sci Info
A 90-day feeding study with whole food and feed in rodents is 
performed for each of the single transformation event. 
A 90-day feeding study with whole food and feed in rodents with 
the GM plant containg the stacked transformation events is 
included, where indications of potential adverse effects are 
identified (i) the stability of the inserts, (ii) the expression of the 
inserts and (iii) the potential synergistic or antagonistic effects 
resulting from the combination of the transformation events.
Minimum of two test doses and a negative control
The highest dose is the maximum achievable without causing 
nutritional imbalance; the lowest dose is above the anticipated 
human/target animal intake level
The GM food and feed analysed is relevant to the product to be 
consumed
For herbicide tolerant GM plants, the tested material comes 
from the GM plant exposed to the intended herbicide
Information on natural variation of test parameters is derived 
from historical background data
Statistical analysis focuses on the detection of possible 
differences between the test material and its control.
A power analysis to estimate a sample size capable of detecting 
a pre-specified biologically relevant effect size with a specified 
power and significance level
Discussion on the need to perform such studies, based on 
outcome from Sections 1.4.1, 1.4.2, 1.4.3 and 1.4.4. 
Reproductive or developmental toxicity test
Discussion on the need to perform such studies, based on 
outcome from Sections 1.4.1, 1.4.2, 1.4.3 and 1.4.4.
The toxicity study design with GM food and feed should follow OECD TG 408 with adaptation
1.4.4.2 Animal studies with respect to reproductive and developmental toxicity testing
1.4.4.3 Other animal studies to examine the safety and the characteristics of GM food and 
feed (see also Sections 1.6.1 and 1.6.2)Part II - Sci Info
Feeding studies with target animal species, focusing on the 
safety of new constituents, on the identification and 
characterisation of unintended effects, and on the nutritional 
impact of any intentional, substantial, compositional 
modifications of the GM plant
Plant materials used in such studies are suitable for diet 
inclusion and can be nutritionally matched to a suitable control 
diet
 - effects specific for the test animal, but not for humans
 - dose-response relationships in parameters that have changed
 - when a difference is noted only at the highest dose applied, 
other factors are considered to determine whether there is a 
relationship with treatment. 
 - information on the background variability in a given parameter
 - evaluation of changes occurring in animals of one gender in 
tests where animals of both genders are used 
 - identify possible inter-relationships between observed 
changes in single parameters
 - supportive data, including in vitro and in silico experiments, to 
explain the observed effect
(a) potential adverse effects identified in other parts of the 
safety assessment have been confirmed or discarded;
(b) the available information on the newly expressed protein(s) 
and other new constituents resulting from the genetic 
modification gives indications of potential adverse effects in 
particular, whether and at which dose levels adverse effects 
were identified in specific studies;
Evaluation of effects observed in the animal trials to identify potential consequences for human 
and animal health. Attention is paid to the following:
The conclusion of the toxicological assessment shall indicate whether:
1.4.5 Conclusion of the toxicological assessment
1.4.4.4 Interpretation of relevance of animal studiesPart II - Sci Info
(c) the information on natural constituents of which the levels 
are different from those in its conventional counterpart provides 
indications of potential adverse effects, in particular, whether 
and at which dose levels adverse effects were identified in 
specific studies;
(d) adverse effects have been identified from the studies made 
on the whole genetically modified food and feed and at which 
dose levels.
Evaluate the result of the toxicological assessment in the light of 
anticipated intake of the GM food and feed 
 
 
Verification whether the source of the transgene is allergenic
When the introduced genetic material is obtained from wheat, 
rye, barley, oats or related cereal grains, assessment of the 
newly expressed proteins for a possible role in the elicitation of 
gluten-sensitive enteropathy or other enteropathies which are 
not IgE-mediated.
For stacked transformation events, assessment of any potential 
for increased allergenicity to humans and animals that may 
arise from additive, synergistic or antagonistic effects of the 
gene products.
1.5.1 Assessment of allergenicity of the newly expressed protein
Comments (up to 500 characters)
Please insert your comments here
1.5 Allergenicity assessmentPart II - Sci Info
 - a search for sequence homologies and/or structural 
similarities to identify potential IgE cross-reactivity 
 - quality and the comprehensiveness of the databases are state 
of the art 
 - the alignment-based criterion meets the minimal requirement, 
i.e. 35 % sequence identity to a known allergen over a window 
of at least 80 amino acids.
 - Sequence alignment parameters used in the analysis, 
including calculation of percent identity (PID) on a window of 80 
amino acids with gaps 
  - for assessing short peptidic fragments such as ORFs, a 
search for sequences of contiguous identical or chemically 
similar amino acid residue can be conducted.
i) the source of the introduced gene is considered allergenic, 
even if no sequence homology of the newly expressed protein 
to a known allergen is demonstrated; or  
ii) the source is not known to be allergenic, but there are 
indications of a relationship between the newly expressed 
protein and a known allergen, based on sequence homology or 
structure similarity.
Specific serum screening study report using individual sera from 
individuals with a proven and well-characterised allergy to the 
source or to the potentially cross-reacting allergen using 
relevant immunochemical tests.
 
Pepsin resistance test performed under standardised 
conditions.
 a) Amino acid sequence homology comparison between the newly expressed protein and known 
allergens
(b) Specific serum screening 
A weight of evidence approach, followed in the assessment of possible allergenicity of the newly 
expressed protein(s), includes: 
Specific serum screening shall be performed when:
(c) Pepsin resistance and in vitro digestibility testsPart II - Sci Info
The digestibility of the newly expressed proteins in specific 
segment of the population may be assessed using in vitro 
digestibility tests using different conditions than those used in 
the pepsin resistance test.
Additional in vitro digestibility tests to take into account the 
impact of the possible interaction between the protein and other 
components of the matrix, as well as the effects of the 
processing.Part II - Sci Info
Depending on the outcome of the in vitro digestibility test, a 
comparison of the intact, the heat-denatured and the pepsin-
digested proteins for IgE binding.
in vitro cell based assays or in vivo tests on animal models
 
When the recipient plant is known to be allergenic,
assessment of any potential change in the allergenicity of the 
GM food or feed by comparison of the allergen repertoire with 
that of its conventional counterpart, in particular, the potential 
over-expression of natural endogenous allergens.
Where available, information on the prevalence of allergy in 
persons working with, coming into contact with or in the vicinity 
of GM plant cultivation.
When known functional aspects of the newly expressed protein 
or structural similarity to known strong adjuvants may indicate 
possible adjuvant activity, assessment of the possible role of 
these proteins as adjuvants. 
Information on the interactions with other constituents of the 
food matrix and/or processing which may alter the structure and 
bioavailability of the adjuvants
(a) whether the novel protein(s) is likely to be allergenic;
(b) whether the GM food or feed is likely to be more allergenic 
than its conventional counterpart.
When there is a likelihood of increased allergenicity due to the 
genetic modification, the GM food or feed is further 
characterised in the light of its anticipated intake.
Proposal of appropriate conditions for placing on the market 
(such as post-market monitoring and labelling).
1.5.4  Conclusion of the allergenicity assessment
The conclusion of the allergenicity assessment shall indicate:
(d) Additional tests
1.5.2 Assessment of allergenicity of the GM food or feed 
1.5.3  AdjuvanticityPart II - Sci Info
 
Determination of the necessity to perform nutritional studies for 
GM food  
When nutritional studies are conducted, the control diet(s) 
include the conventional counterpart and where appropriate 
additional comparator(s). 
In the case of herbicide tolerant GMd plants, the tested material 
should come from the GM plant exposed to the intended 
herbicide. 
In cases where an altered bioavailability needs to be 
established and may raise concern for sub-population(s), the 
level of the nutrient in the food shall be determined, taking into 
account all the different forms of the compound.
The selection of test methods for bioavailability depends on the 
nutrient or other constituent, the food containing these 
constituents, as well as the health, nutritional status and dietary 
practices of the specific population(s) anticipated to consume 
the food.
Determination of the necessity to perform nutritional studies for 
GM feed  
When nutritional studies are conducted, the control diet(s) 
include the conventional counterpart and where appropriate 
additional comparator(s). 
When GM feed with improved nutritional characteristics, feeding 
studies with target animal of food producing species are 
conducted to assess the impact on the feed.
1.6.2 Nutritional assessment of the genetically modified feed
Comments (up to 500 characters)
Please insert your comments here
1.6 Nutritional assessment
1.6.1 Nutritional assessment of the genetically modified foodPart II - Sci Info
When GM plants modified for improved content and 
bioavailability of nutrients, studies with target food producing 
animal species are conducted to determine the bioavailability of 
individual nutrients in the GM plant compared to its conventional 
counterpart. 
When GM plants with traits to enhance animal performance 
through increased nutrient density (such as increased oil 
content) or an enhanced level of a specific nutrient (such as an 
essential amino acid or a vitamin), an appropriate control diet 
using its conventional counterpart is formulated by 
supplementing it with the specific nutrient to the extent of the 
change effected in the GM plant. 
Co-products (such as oilseeds meals) of GM plants may be 
compared with co-products produced from the conventional 
counterpart.
The exact experimental design and statistical approaches 
depends on the targeted animal species, type of plant trait(s) 
studied and the size of the expected effect. 
When appropriate, feeding studies in food producing animals to demonstrate that the nutritionally 
improved GM plant fulfils the expected nutritional valuePart II - Sci Info
 - span the growing and/or finishing period to slaughter for 
chickens, pigs, and cattle for fattening, or
 - a major part of a lactation cycle for dairy cows, or
 - laying cycle for laying hens or quails
 - for feedstuffs intended only for aquaculture, growth studies 
conduct with aquatic species such as carp, catfish, salmonidae 
or typical herbivores.
The experimental diets are formulated in such a way that the 
key measured endpoints are responsive to a difference in the 
quantity and/or availability of the nutrient in question.
Endpoint measurements shall vary with the target species used 
in the study, but shall include feed intake, body weight, animal 
performance and bioavailability of nutrients.
Indication whether the GM food and feed is nutritionally 
equivalent to its conventional counterpart, taking natural 
variations into account.
Evaluation the result of the nutritional assessment in the light of 
anticipated intake of the GM food and feed.
 
Toxicity tests use internationally agreed guidelines and test 
methods described by Council Regulation (EC) No 440/2008
Where necessary, they are used in a possibly adapted form for 
GMO toxicological testing
An estimate of the expected intake is provided  for the 
nutritional evaluation.
2. Exposure assessment - Anticipated intake/extent of use
1.7 Standardised guidelines for toxicity tests
Target animal feeding studies - species and duration:
1.6.3 Conclusion of the nutritional assessment
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
 - the intended function, the dietary role, and the expected level 
of use of the GM food and feed in the EU
 - the expected range of concentrations of newly produced 
proteins or existing plant proteins deliberately modified in the 
GM food(s) and feed(s) to be placed on the market 
 - recent developments in methodologies and appropriate 
consumption data are used  
 - describe any assumptions made in the exposure assessment
 
 - on the basis of representative consumption data for products 
obtained from the respective conventional plants, estimation of 
the anticipated average and maximum intake of the GM food 
and feed.
 - data on import and production quantities may provide 
additional information for the intake assessment
 - probabilistic methods may be used to determine ranges of 
plausible values rather than single values or point estimates.
 - identify and consider particular groups of the EU population 
with an expected higher exposure and consider this higher 
exposure within the risk assessment
 - expected intake of these constituents shall be estimated 
taking into account the influences of processing, storage and 
expected treatment of the food and feed in question.
 - in cases where the GM has resulted in an altered level of a 
natural constituent, or if a new constituent occurs naturally in 
other food and feed products, the anticipated change in total 
intake of this constituent is assessed considering realistic as 
well as worst case intake scenarios.
 - information on known or anticipated human/animal intake of 
analogous GM food and feed and on other routes of exposure 
to the respective new and natural constituents, including 
amount, frequency and other factors influencing exposure
Information to be provided:Part II - Sci Info
 
3.1 Introduction
 - based on data from hazard identification, hazard 
characterisation, and on exposure/intake data.
 - Depending on the issue and the available data, perform a 
qualitative and, where possible, quantitative risk 
characterisation.
 - comprehensive by considering all the available evidence from 
several analysis. 
 - demonstrate that the hazard identification and hazard 
characterisation are complete.
 - discuss the quality of existing data and information. The 
discussion shall clearly indicate how this body of information 
has been taken into account in the determination of the final risk 
characterisation.
 - estimate uncertainties associated to each test as well as to 
the different stages of the risk assessment, quantify them to the 
possible extent
 - a distinction made between uncertainties that reflect natural 
variations in biological parameters and variation amongst 
different species' responses. 
 - the conditions for the estimated risk, and associated 
uncertainties, are as precise as possible.
 - consider indications resulting from the risk characterisation 
that may require specific activities for post-market monitoring of 
GM food and feed.
3.2 Issues to be considered for risk characterisation
Risk characterisation shall be carried out in an integrative manner: 
Comments (up to 500 characters)
Please insert your comments here
3. Risk characterisationPart II - Sci Info
3.2.1 Molecular characterisation
3.2.1 Comparative analysis 
3.2.3 Food and feed safety in relation to intake 
(a) The GM food and feed has no adverse effects on human 
and animal health
(b) The GM food does not differ from the food which it is 
intended to replace to such an extent that its normal 
consumption would be nutritionally disadvantageous for the 
consumer
(c) The GM food does not mislead the consumer;
(d) The GM feed does not harm or mislead the consumer by 
impairing the distinctive features of the animal products
(e) The GM feed does not differ from the feed which it is 
intended to replace to such an extent that its normal 
consumption would be nutritionally disadvantageous for animals 
or humans
clearly indicate what assumptions have been made during the 
risk assessment in order to predict the probability of occurrence 
and severity of adverse effect(s) in a given population, and the 
nature and magnitude of uncertainties associated with 
establishing these risks
include detailed information justifying the inclusion or not of a 
proposal for labelling in the application
Based on the outcome of the risk assessment, discussion on 
the necessity to provide a post-market monitoring (PMM) 
proposal.
The final risk characterisation shall clearly demonstrates that
3.3 The result of risk characterisation 
4. Post-market monitoring on the genetically modified food or feed
Post-market monitoring should only be considered in cases where, notwithstanding the fact that 
the safety of genetically modified food and feed has been demonstrated, it is appropriate to 
confirm the expected consumption, the application of conditions of uses or identified effects. Part II - Sci Info
A PMM is proposed to confirm: (a) that specific 
recommendations of uses are followed by the consumer/animal 
owner;
(b) the predicted consumption of the genetically modified food 
or feed; or
(c) the relevance and intensity of effects and unintended effects 
detected during the pre-market risk assessment which can only 
be further characterised by post-market monitoring
The PMM strategies are described 
The PMM is accompanied by adequate justification and a 
thorough description of the selected methodologies including 
aspects related to the analysis of the collected information
 
 
ERA is science-based, transparent and performed on a case-by-
case basis
      - follows a systematic approach (6 steps, 7 areas of risks)
      - follows a comparative approach
      - addresses uncertainties
 The ERA considers
       - immediate and/delayed, direct and indirect effects
       - intended effects
       - unintended effects (event-specific) taking into account the 
data collected/generated from 
General approach of the ERA 
Comments (up to 500 characters)
Please insert your comments here
5. Environmental Assessment 
Scientific requirements for the environmental assessment as outlined in the EFSA guidance on the ERA of GM plants (2010)Part II - Sci Info
            i) the molecular characterisation
           ii) the compositional analysis
          iii) the agronomic and phenotypic characterisation
          iv) the GM plant-environment interactions taking into 
account in planta data
The ERA considers the scope of the application and the 
different levels and routes of exposure to the GM plant
Description of comparator(s) 
Assessment of similarities and differences in the interaction of 
the GM plant and the environment in relation to conventional 
counterpart (where feasible and appropriate)
For vegetatively propagated crops, the conventional counterpart 
shall, in principle, be the non-GM near-isogenic line  
For sexually reproducing crops, the conventional counterpart 
shall have a genetic background as close as possible to the GM 
plant under assessment  
The conventional counterpart, if available, should be used as 
the comparator 
If the conventional counterpart not available, 
           - non GM line derived from the breeding scheme used to 
develop the GM plant
           - non GM line with agronomic properties as similar as 
possible to the GM plant containing the stacked events
The following information is provided
Choice of comparators 
For GM plants containing single events
The issues outlined in the EFSA ERA guidance chapters 2.3.1 - choice of comparator, 2.3.2- 
receiving environment, 2.3.3 - general statistical principles, 2.3.4 - long-term effects and 2.3.5 - 
risk assessment of GM plants containing stacked transformation events should be considered 
throughout the ERA. EFSA does not expect a dedicated section on these chapters in the 
submitted application.      
For GM plants containing stacked events Part II - Sci Info
      - Breeding scheme of the GM plant  
      - Breeding scheme of all chosen comparator(s)   
      - Justification for the selection of the comparator(s) 
      - Details and justification of treatments and management 
regimes
        - characteristics of the receiving environments  
        - representative management systems  
        - range of relevant biotic and abiotic interactions  
Justification of representativeness of the receiving 
environments  
Justification of representativeness of the selected management 
systems    
Consideration of a worst-case scenario 
Consideration of the presence of other GM plants in the same 
receiving environments   
Justification that the generated data are relevant for other 
receiving environments and risk conclusions are valid for other 
receiving environments
 
An overview of statistical design and analysis for each study 
presented in the ERA part of the application  
For each ERA related study, Appendix F -ERA-statistical design 
and analysis is compiled  
 - Discussion of the level of uncertainty in the ERA in 
comparison with the current uncertainties displayed in the 
scientific literature
 
 - Description of the types of uncertainties encountered and 
considered during the different risk assessment steps (steps 1 
to 5)
Receiving environments 
General statistical principles 
The relevant receiving environment(s) is/are described including the following:
Consideration of uncertaintiesPart II - Sci Info
 - Description of the relative importance of these types of 
uncertainties and their influence on the assessment outcome 
 
 - Highlight and quantification as far as possible of uncertainties 
inherent in the different steps of the ERA 
 - Definition as precisely as possible of the terms for the 
expression of risks and associated uncertainties 
Potential long-term effect(s) are identified and described by a 
desk study in the 7 areas of risk (chapters 3.1-3.7 of the ERA 
guidance document) and classified according to
 
        - category 1 of long-term effects: result of chronic 
exposure 
        - category 2 of long-term effects: result of increase in 
spatial and temporal complexity
The long-term effects are addressed in each specific area of 
risk including  
        - methods, approaches and data sets used to reach 
conclusions
        - the basis of and justification for the conclusions
        - cross-link to parts of the post-market environmental 
monitoring (PMEM) plan designed to observe possible long-
term effects
 
 
       identification of potential hazards
       identification of pathways of exposure (plant / environment)
       identification of aspects of the environment to be protected 
(protection goals) 
       risk hypothesis to be tested
Specific areas of risks
5.1. Persistence and invasiveness including plant-to-plant gene flow
5.1.1 Step 1: Problem formulation
Long-term effects 
A problem formulation is given includingPart II - Sci Info
       definition of assessment & measurement endpoints
       definition of acceptable effect size (limits of concern)
       information on the conditions of the production systems and 
relevant semi-natural and natural habitats
          - the reproductive biology 
          - the characteristics associated with weediness and 
invasiveness
          - the factors limiting persistence and invasiveness
          - the hybridisation and introgression potential with any 
sympatric compatible relatives 
           - the seed germination characteristics (see Appendix C 
ERA agronomic characteristics)
           - the phenotype under agronomic conditions
             For each field trial the following Appendices are 
compiled: 
         Appendix C ERA agronomic characteristics
        Appendix F ERA statistical design and analysis
           - the reproductive biology of the GM plant 
           - the potential for seed persistence leading to volunteer 
occurrence 
         Potential unintended effects, resulting from the 
transformation process, have been shown not to alter the 
fitness of the GM plant compared to the conventional 
counterpart in stage 1? 
          if YES, then GM trait specific information can be used in 
the subsequent stages
5.1.2 Step 2: Hazard characterisation
Species-specific background information   
Description of the parental species including information on 
Stage 1: Event-specific information on   
Conclusions of stage 1 assessment Part II - Sci Info
For plants that can either reproduce or overwinter in the EU 
consideration of stage 2 
a) Will the GM plant be more persistent than conventional 
counterpart under agricultural conditions?
b) Will the GM trait increase the fitness of the GM plant or 
compatible relative under agricultural conditions?
c) Can the GM plant form feral populations under EU 
conditions?
d) Can the GM plant hybridise with sympatric compatible 
relatives outside production systems?
Conclusions of stage 2 assessment 
a) Will the GM trait alter the fitness of feral plants or compatible 
relatives in semi-natural habitats? 
b) Will the GM trait alter the range of feral plants or populations 
of compatible relatives?
Conclusions of stage 3 assessment 
a) Will the GM trait caused populations of feral plants or 
compatible relatives to change in size?
Conclusions of stage 4 assessment 
Exposure characterisation for each hazard identified in step 
3.1.1 and 3.1.2
Identification and description of pathway(s) of exposure 
5.1.3 Step 3: Exposure characterisation
If feral populations are likely and/or if hybridisation is plausible: Stage 3: Trait-specific 
information  
The applicant has addressed the following questions (see Figure 4 of the ERA guidance document 
2010)
The applicant has addressed the following questions (see Figure 4 of the ERA guidance document 
2010)
If altered fitness or the ability to occupy new niches are demonstrated: Stage 4: Trait-
specific information 
The applicant has addressed the following question (see Figure 4 of the ERA guidance document 
2010)
For plants that can either reproduce or overwinter: Stage 2: Trait-specific information Part II - Sci Info
Risk characterisation is provided for all identified risks 
Information on the acceptability of the characterised risk(s) 
(within the range defined as acceptable during the problem 
formulation)
Information on whether any risk management strategies are 
needed 
If needed, proposal and definition of the management strategies 
Assessment of efficacy and reliability of each management 
strategy 
Information on the expected reduction in risk associated with 
the management strategies 
Cross link with PMEM taking into account risk management 
strategies
 - the impact of the GM plant and/or hybridising relatives in the 
production systems 
 - the impact of the GM plant and/or hybridising relatives in semi-
natural and natural habitats  
 - the acceptability of the anticipated harm  
 - the risk management strategies needed to mitigate any harm 
 
5.1.4: Step 4: Risk characterisation
5.2. Plant to micro-organisms gene transfer 
5.2.1 Step 1: Problem formulation
A problem formulation is given including
5.1.5: Step 5: Risk management strategies
5.1.6: Step 6: Conclusions
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
       identification of potential hazards
       identification of pathways of exposure (plant / environment)
       identification of aspects of the environment to be protected 
(protection goals) 
       risk hypothesis to be tested
       definition of assessment & measurement endpoints
       definition of acceptable effect size (limits of concern)
       - the molecular characterization of the DNA sequence 
inserted, including promoters is given  
       - the presence of antibiotic marker gene (ARM) 
       - the homologies between inserted plant DNA sequences 
and DNA sequences from relevant microbial recipients   
       - the presence of recipient micro-organisms for transgenic 
DNA in the receiving environment(s)
       - Selective conditions enhancing the probability of 
dissemination and maintenance of the genetic material from the 
GM plant in natural microbial communities
      - the persistence of the GM plant material after harvest  
      - the potential for long-term establishment of the genetic 
material from the GM plants in natural microbial communities   
Characterisation of each hazard identified in step 3.2.1 
Assessment of prevalence and distribution of genes 
Exposure characterisation for each hazard identified in step 
3.2.1 and 3.2.2
       - the sub-cellular location and copy number of the 
recombinant DNA 
5.2.2 Hazard characterisation
Exposure characterisation is taking into account  
The problem formulation should focus on
5.2.3 Step 3: Exposure characterisationPart II - Sci Info
       - the environmental routes of exposure of the GM plants 
and the recombinant DNA 
       - the stability of the DNA in the relevant environment(s) 
        - the plant production system
        - the food and feed chain
        - the gastro-intestinal system
       - the estimated probability of occurrence   
       - any positive selection pressure in receiving environment
       - the magnitude of the consequences of the adverse 
effect(s)   
Information on whether any risk management strategies are 
needed 
If needed, proposal and definition of the management strategies 
Assessment of efficacy and reliability of each management 
strategy 
Information on the expected reduction in risk associated with 
the management strategies 
Cross link with PMEM taking into account risk management 
strategies
Conclusions taking into account any proposed risk management 
strategie(s)
The potential impacts are also evaluated for indirect effects on 
biogeochemical cycles
5.2.4: Step 4: Risk characterisation
The exposure characterisation is considering the different routes of exposure in the receiving 
environment(s):
5.2.5: Step 5: Risk management strategies
5.2.6: Step 6: Conclusions
Risk characterisation is provided for each identified risk, e.g. by estimating Part II - Sci Info
 
Description of the target organisms  
       identification of potential hazards
       identification of pathways of exposure (plant / environment)
       identification of aspects of the environment to be protected 
(protection goals) 
       risk hypothesis to be tested
       definition of assessment & measurement endpoints
       definition of acceptable effect size (limits of concern)
Evaluation of the potential hazards identified in step 1 e.g. for 
the target organisms to develop resistance  
    - the biology, life cycle, ecology and/or behaviour of the target 
organisms
    - the resistance mechanisms
    - the heritability and linkages to virulence, fitness and 
selective advantage
    - the distribution of the target organism and its resistant 
populations in European environments 
    - the host range of the target organism 
    - the population genetics and epidemiology of susceptible 
and resistant target organisms 
Background information on
5.3 Interactions between the GM plant and target organisms
5.3.1 Step 1: Problem formulation
5.3.2 Step 2: Hazard characterisation
A problem formulation is given including
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
    - the frequency of resistant individuals or resistance allele(s) 
    - the mode of action of the transgenic products towards the 
target organisms
    - the baseline susceptibility of the target organisms to the 
transgenic products 
Various scenarios are considered, including a worst case 
scenario  
     - expression level of the transgenic products in plant tissues 
consumed by TO  
     - estimation of the levels of intake of the transgenic 
product(s) at various development stages of the target 
organisms  
     - influence of the expression level and its variability on the 
interaction between the GM plant and the target organism  
     - proportion of the population of the target organisms 
exposed to the GM plant in the receiving environment(s)  
     - baseline frequency of resistant individuals or 
resistance/virulence alleles  
     - deployment of other GM plants expressing similar traits in 
the receiving environment  
       - evolving resistance   
       - developing undesired changes in the interaction between 
the target plant pathogens and the GM plants in the receiving 
environment(s)   
Information on whether any risk management strategies are 
needed 
If needed, proposal and definition of the management strategies 
5.3.3 Step 3: Exposure characterisation
5.3.4: Step 4: Risk characterisation
5.3.5: Step 5: Risk management strategies
Data characterising the exposure of target organisms to the GM plants should include
Risk characterisation is provided for each identified risk identified, e.g.Part II - Sci Info
Assessment of efficacy and reliability of each management 
strategy 
Information on the expected reduction in risk associated with 
the management strategies 
An IRM plan is presented
            Annex II-ERA-IRM is compiled 
Cross link with PMEM taking into account risk management 
strategies
Conclusions taking into account any proposed risk management 
strategie(s)
 
        - the plant and the objective of the inserted trait(s) are 
clearly described 
        - the receiving environments are clearly described 
        - the selected NTO focal species are clearly described 
        - the selected NTO focal species are commonly present in 
European environments 
        - if the NTOs are NOT commonly present in European 
environments, are justifications provided? 
       identification of potential hazards 
       identification of pathways of exposure of NTOs to 
plant/plant products)
5.3.6: Step 6: Conclusions
Comments (up to 500 characters)
Please insert your comments here
5.4 Interactions of the GM plant with non-target organisms (NTOs)
5.4.1 Step 1: Problem formulation
A problem formulation is given including
The following elements are consideredPart II - Sci Info
       identification of aspects of the environment to be protected 
(protection goals) 
       risk hypothesis to be tested
       definition of assessment & measurement endpoints
       definition of acceptable effect size (limits of concern)
Was the stepwise approach (Figure 5 of the ERA GD 2010) 
followed to select focal NTO species to be tested ?
                       step 1: identification of NT functional groups likely 
to be exposed to the GM plant 
                       step 2:categorisation of NT species from 
identified functional groups
                           did you also consider endangered NT species 
or species of economic/cultural value? 
                       step 3: ranking species based on the ecological 
criteria
                       step 4: final selection of focal species
Was a tiered approach followed to assess effects on NTO? 
Did you test at least one focal NTO species per functional group 
identified?  
Did you provide tier 1a studies?  
Did you provide tier 1b (in planta) studies?  
Did you provide tier 2 studies? 
          If not, justification provided
Did you provide tier 3 studies? 
          If not, justification provided
For each tier study provided, please indicate the selected 
assessment and measurements endpoints, the experimental 
details of the study and the trigger values to move between tiers 
(see Appendix E)
Appendix E - ERA NTO
5.4.2 Step 2: Hazard characterisation
According to this stepwise approach, did you address the following questions Part II - Sci Info
Appendix F - ERA statistical design and analysis
Did you also assess unintended effects based on a weight-of-
evidence approach?
          (1) molecular data
          (2) compositional data
          (3) data from agronomic & phenotypic field trials
          (4) GM plant-environment interactions taking into account 
in planta data  
       Did you provide field-generated data from outside EU?
The exposure of NTO to the newly inserted product(s)/GM plant 
is evaluated, considering the   
(0) scope of the application,
(1) characteristics of the NTO (e.g. spatial distribution, trophic 
levels, feeding habits)
(2) characteristics of the GM plant, its transgene(s) and the 
products thereof (e.g. spatial distribution, pollen dispersal & 
deposition, time/location of pollen, shed, product concentration 
in the various parts of the plant over the growing season)
(3) characteristics of the host plant(s) (e.g. range and spatial 
distribution of host plants) 
(4) and other external factors (e.g. rainfall, agricultural 
management practices) 
Risk characterisation is provided for each identified risk. 
         (1) in the production site of the GM plant?
         (2) outside the production site in different habitats where 
relevant exposure of sensitive NTO may occur?
5.4.3 Step 3: Exposure characterisation 
5.4.4: Step 4: Risk characterisation
       Did you consider the following data?
     Specific characterization and quantification of the identified risk(s) for each selected endpointPart II - Sci Info
Information on whether any risk management strategies are 
needed 
If needed, proposal and definition of the management strategies 
Assessment of efficacy and reliability of each management 
strategy 
Information on the expected reduction in risk associated with 
the management strategies 
Cross link with PMEM taking into account risk management 
strategies
        Were the management strategies designed for worst-case 
scenario of high exposure?
        Do they comply with common principles of good 
agricultural  practices like crop rotations, integrated pest 
management?
        (1) in the production site of the GM plant
        (2) outside the production site in different habitats where 
relevant exposure of sensitive NTO may occur?
Conclusion on intended effects on NTOs
Conclusion on unintended effects on NTOs
 
5.4.5: Step 5: Risk management strategies
5.4.6: Step 6: Conclusions
Comments (up to 500 characters)
Please insert your comments here
5.5 Impacts of the specific cultivation, management and harvesting techniques 
5.5.1 Step 1: Problem formulation
A problem formulation is given including
The conclusions are provided, taking into account any proposed risk management strategie(s)Part II - Sci Info
       identification of potential hazards
       identification of pathways of exposure (plant / environment)
       identification of aspects of the environment to be protected 
(protection goals) 
       risk hypothesis to be tested
       definition of assessment & measurement endpoints
       definition of acceptable effect size (limits of concern)
Identification of the various representative management and 
production systems in which the GM plant might be introduced 
Identification of potential changes of receiving environment(s) 
and management and production systems which are 
foreseeable in the near future 
Description how the introduction of the GM plant might alter the 
existing management and production systems, taking into 
consideration direct and indirect effects 
Identification of relevant assessment endpoints representing the 
aspects of the environment(s) that need to be protected from 
adverse effects due to changes in cultivation, management and 
harvesting techniques.
Identification of the potential adverse effects that may result 
from the changes in management and production systems in a 
range of different environments, taking account of anticipated 
future changes in agriculture associated with other drivers
For each representative management and production system: 
Identification of the possible environmental adverse effects due 
to the change in management practices and cultivation 
practices, including the cultivation of other plants   
- Consideration of the potential impact of the GM plant on the
cultivation of other plants and of its consequences. 
- Consequences of risk management measures identified in
other chapter sections are being considered ;
5.5.2 Step 2: Hazard characterisation Part II - Sci Info
Information on the potential long-term and indirect 
environmental impacts of the management and production 
systems in countries where the GM plant is/has been grown 
(even outside EU) 
Models are used to support the risk assessment
      - a "field level" or "substitution" scenario is described  
      - a "landscape scenario" or "typical" scenario is described   
      - a "worst-case" scenario is described  
A "fourth" scenario is described considering the potential 
adoption of other GM plants in the receiving environment
Models are used to support the scenario analysis 
Risk characterisation is provided for each scenario analysis, 
e.g. assessment as to whether the specific GM management 
practices cause greater, similar or lower adverse environmental 
effects than the current management and production systems 
they are likely to replace  
Models are used to complement applicant's statement and 
clarify uncertainties 
Information on whether any risk management strategies are 
needed 
If needed, proposal and definition of the management strategies 
Assessment of efficacy and reliability of each management 
strategy 
Information on the expected reduction in risk associated with 
the management strategies 
Cross link with PMEM taking into account risk management 
strategies
5.5.3 Step 3: Exposure characterisation
5.5.4: Step 4: Risk characterisation
5.5.5: Step 5: Risk management strategies
Information on whether
3 scenarios for exposure characterisation are considered  Part II - Sci Info
      - the proposed management and production systems are 
consistent with the environmental protection goals   and 
      - the strategies proposed do not pose more harm than non-
GM management strategies  
Models are used to complement applicant's statement and 
clarify uncertainties
Conclusions taking into account any proposed risk management 
strategie(s)
The conclusions are taking into account effects of further 
potential changes in the receiving environment(s) and farming 
systems  
 
       identify potential hazards
       identify pathways of exposure (plant / environment)
      identify aspect of the environment to be protected 
(protection goals) 
      formulate risk hypothesis to be tested
      define assessment & measurement endpoints
      define acceptable effect size (limits of concern)
Identify if GM plants and their associated management have 
potential adverse effects on biogeochemical processes 
compared to the effects of a range of current production 
systems (link to 5.5)
5.5.6: Step 6: Conclusions
Comments (up to 500 characters)
Please insert your comments here
5.6 Effects on biogeochemical processes 
5.6.1 Step 1: Problem formulation
A problem formulation is given includingPart II - Sci Info
      - at production site
      - in the wider environment
An assessment is provided whether the hazard identified in step 
1  would have additional adverse effects relative to current 
production practice  
The exposure of the hazard characterised in step 2 are 
discussed  
The assessment of the GM plant and its management affecting 
biogeochemical processes in the production site is provided  
The assessment of the GM plant and its management affecting 
biogeochemical processes in the wider environment is provided  
The assess the potential exposure to GM plant products 
through manure or organic plant matter, (imported as fertilizer 
or soil amendment derived from faeces animal fed GMO) or 
derived from other bioproducts of industrial processes is 
provided  
Risk characterisation is provided for each risk identified and is 
carried out both at the production site and in the wider 
environment
The risk characterisation demonstrates that the GM plant and 
its management do not have more adverse effects on 
biogeochemical cycles than any present system
Information on whether any risk management strategies are 
needed 
If yes, the management strategies are proposed and defined 
The efficacy and reliability of each management strategy are 
discussed
5.6.2 Step 2: Hazard characterisation
5.6.3 Step 3: Exposure characterisation
5.6.4: Step 4: Risk characterisation
5.6.5: Step 5: Risk management strategiesPart II - Sci Info
The final level of risk, after applying the management strategies, 
is provided
Cross link with PMEM taking into account risk management 
strategies
The conclusions are provided, taking into account any risk 
management strategies   
The conclusions consider in both production site and the wider 
environment   
The conclusions consider long-term effects of adverse changes 
in biogeochemical processes and address indirect effects on 
biogeochemical processes as a consequences of altered 
production practices related to GM plant   
The issue is considered in the application
Reference is given to the food and feed safety assessment
If the application is for non-food or non-feed purposes, 
reference is given to the EFSA GMO Panel guidance document 
(EFSA, 2009)
The overall evaluation of the risk of the GM plant in the 
receiving environment(s) is provided
    - the risk characterisation 
    - any risk management strategies proposed
    - assumptions made during the ERA 
    - nature and magnitude of the uncertainties associated 
Cross link with PMEM taking into account risk management 
strategies
Plan for General Surveillance (GS)
5.6.6 Step 6: Conclusions
5.7. Effects on human and animal health
5.8. Overall risk evaluation and conclusions 
6. PMEM 
The overall evaluation is taking into account Part II - Sci Info
Consideration of the scope of the application and the level of 
exposure
    - GMO-focused systems like farmer questionnaires
    - existing monitoring networks
    - literature review
Identification of risk(s) or critical uncertainty during the ERA
A Case-Specific Monitoring (CSM) plan is provided considering 
the risk(s) identified during the ERA including any uncertainty on 
risk management measures
An Insect-Resistant Management (IRM) plan is provided
If yes,
   - Appendix D - ERA IRM is compiled
   - A strategy for managing resistance (e.g. High dose/Refuge) 
is provided 
   - A proposal to monitor the implementation of resistance 
management measures is provided
   - A proposal to monitor the change in susceptibility of target 
pests is provided
Information on data quality, management and statistical 
analyses
Reporting the results of monitoring on an annual basis
Review and adaptation proposed
7. Additional information related to the safety of the genetically modified food or feed
The GS plan relies on the following tools:
Comments (up to 500 characters)
Please insert your comments herePart II - Sci Info
A systematic review of studies published in the scientific 
literature and studies performed by the applicant within the 
period of 10 years prior to the date of submission of the dossier 
on the potential effects on human and animal health of the GM 
food and feed covered by the application is included in the 
application. 
This systematic review is carried out by taking into account the 
guidance of EFSA on application of systematic review 
methodology to food and feed safety assessments to support 
decision making.
Where the information obtained from those studies is not 
coherent with the information obtained from the studies 
performed in accordance with the requirements set out in Annex 
II of the Implementing Regulation, a thorough analysis of the 
respective studies and plausible explanations for the observed 
discrepancies are provided.
End of this spreadsheetPart III Cartagena Protocol
Part III - Cartagena Protocol
Yes, 
provided 
Not applicable 
(justification 
provided in Part III)
EFSA agrees 
EFSA 
comments/questions 
to applicants
For GM plants containing stacked transformation events 
(segregating crops), the information provided in Part III 
includes all sub-combinations not yet authorised 
(a)    The name and contact details of the applicant for a 
decision for domestic use
(b)    The name and contact details of the authority 
responsible for the decision
(c)    Name and identity of the GMO
(d)    Description of the gene modification, the technique 
used, and the resulting characteristics of the GMO
e) Any unique identification of the GMO
(f)    Taxonomic status, common name, point of collection or 
acquisition, and characteristics of recipient organism or 
parental organisms related to biosafety
(g)    Centres of origin and centres of genetic diversity, if 
known, of the recipient organism and/or the parental 
organisms and a description of the habitats where the 
organisms may persist or proliferate
(h)    Taxonomic status, common name, point of collection or 
acquisition, and characteristics of the donor organism or 
organisms related to biosafety 
(i)    Approved uses of the GMO
(j)    A risk assessment report consistent with Annex II to 
Directive 2001/18/EC
     1. Identification of characteristics which may cause 
adverse effects
For EFSA use onlyPart III Cartagena Protocol
     2. Evaluation of the potential consequences of each 
adverse effect, if it occurs
     3. Evaluation of the likelihood of the occurence of each 
identified potential adverse effect 
     4. Estimation of the risk posed by each identified 
characteristic of the GMO(s)
     5. Application of management strategies for risks from the 
deliberate release or marketing of GMO(s)
     6. Determination of the overall risk of the GMO(s)
(k)    Suggested methods for the safe handling, storage, 
transport and use, including packaging, labelling, 
documentation, disposal and contingency procedures, where 
appropriate
Comments (up to 500 characters)
Please insert your comments herePart IV Labelling
Part IV - Labelling
Yes, 
provided 
Not applicable 
(justification provided 
in Part IV)
EFSA agrees 
EFSA 
comments/questions to 
applicants
For GM plants containing stacked transformation events 
(segregating crops), the information provided in Part IV includes all 
sub-combinations not yet authorised
(a)    A proposal for labelling in all official languages of the Union, 
where a proposal for specific labelling is required in accordance with 
Articles 5(3)(f) and 17(3)(f) of Regulation (EC) No 1829/2003
(b)    Either a reasoned statement that the food or feed does not 
give rise to ethical or religious concerns or a proposal for labelling in 
all official languages of the Union as required by Articles 5(3)(g) and 
17(3)(g) of Regulation (EC) No 1829/2003
(c)    When appropriate a proposal for labelling complying with the 
requirements of point A(8) of Annex IV to Directive 2001/18/EC
For EFSA use only
Comments (up to 500 characters)
Please insert your comments herePart V Methods of detection
Part V - Methods of detection, sampling and reference 
materials
Yes, 
provided 
Not applicable 
(justification 
provided in Part V)
EFSA agrees 
EFSA 
comments/questions to 
applicants
A copy of the completed form for the submission of those samples 
to the EURL and proof of sending to the EURL
Reference to the place where the reference material can be 
accessed shall be provided in the application.
Proof of reception by the EURL-GMFF about samples, reagents and 
methods  (Appendix G)
Comments (up to 500 characters)
Please insert your comments here
For EFSA use onlyPart VI Add info
Part VI - Additional information to be provided for GM 
plants and/or food/feed containing or consisting of GM 
plants 
Yes, 
provided 
Not applicable 
(justification 
provided in Part VI)
EFSA agrees 
EFSA 
comments/question
s to applicants
The information required in the notification as set out in Annex III to 
Directive 2001/18/EC shall be provided where it is not covered by the 
requirements of other parts of the application. 
For EFSA use only
Comments (up to 500 characters)
Please insert your comments herePart VII - Summary
Part VII - Summary
Yes, 
provided 
Not applicable 
(justification 
provided in Part VII)
EFSA agrees
EFSA 
comments/questions 
to applicants
(a)    Member State of application
(b)    Application number 
(c)    Name of the product (commercial and other names)
(d)    Date of acknowledgement of valid application 
(a)    Name of applicant
(b)    Address of applicant 
(c)    Name and address of the representative of the applicant established in 
the Union (if the applicant is not established in the Union)
      Food containing or consisting oGM plants
      Food produced from GM plants or containing ingredients produced from 
GM plantscontaining or consisting of genetically modified plants
     Feed containing or consisting of GM plants
      Feed produced from GM plants
      Products other than food and feed containing or consisting of GM plants 
with the exception of cultivation
1.2. Applicant
(c)    GM plants for food and feed uses
1.3. Scope of the application
For EFSA use only
1. General Information 
1.1 Details of application
(a) Genetically modified food
(b)    Genetically modified feedPart VII - Summary
      Seeds and plant propagating material for cultivation in the Union
No
If yes, specify
1.5. Has the GM plant been notified under Part B of Directive
2001/18/EC?
Yes
If no, provide risk analysis data
No
If yes, specify
No
If yes, specify
(a) Name of the recipient or parental plant and the intended function of the 
genetic modification
(b) Types of products planned to be placed on the market according to the 
authorisation applied for and any specific form in which the product must not 
be placed on the market (such as seeds, cut-flowers, vegetative parts,) as a 
proposed condition of the authorisation applied for
(c) Intended use of the product and types of users
(d) Any specific instructions and recommendations for use, storage and 
handling, including mandatory restrictions proposed as a condition of the 
authorisation applied for
1.8. General description of the product
1.4 Is the product or the uses of the associated plant protection product(s) already authorised or subject 
to another authorisation procedure within the Union? 
1.6. Has the GM plant or derived products been previously notified for marketing in the Union under Part 
C of Directive 2001/18/EC?
1.7. Has the product been subject to an application and/or authorised in a third country either previously 
or simultaneously to this application?Part VII - Summary
(e) If applicable, geographical areas within the Union to which the product is 
intended to be confined under the terms of the authorisation applied for
(f) Any type of environment to which the product is unsuited 
(g) Any proposed packaging requirements
(h) Any proposed labelling requirements in addition to those required by other 
applicable EU legislation than Regulation (EC) No 1829/2003 and when 
necessary a proposal for specific labelling in accordance with Articles 13(2) 
and (3), Article 25(2)(c) and (d) and Article 25(3) of Regulation (EC) No 
1829/2003 
In the case of products other than food and feed containing or consisting of 
genetically modified plants, a proposal for labelling which complies with the 
requirements of point A(8) of Annex IV to Directive 2001/18/EC must be 
included.
(i) Estimated potential demand
               (i) In the EU
               (ii) In EU export markets
(j) Unique identifier in accordance with Regulation (EC) No 65/2004
1.9. Measures suggested by the applicant to take in the case of 
unintended release or misuse of the product as well as measures for its 
disposal and treatment
(a) Family name
(b) Genus
(c) Species
(d) Subspecies 
(e) Cultivar/breeding line
(f) Common name
2. Inforamtion relating to the recipient or (where appropriate) parental plants
2.1. Complete namePart VII - Summary
2.2. Geographical distribution and cultivation of the plant, including the 
distribution within the Union
(a) Mode(s) of reproduction
(b) Specific factors affecting reproduction 
(c) Generation time 
2.4. Sexual compatibility with other cultivated or wild plant species (for 
environmental safety aspects)
2.5. Survivability (for environmental safety aspects)
(a) Ability to form structures for survival or dormancy
(b) Specific factors affecting survivability 
(a) Ways and extent of dissemination
(b) Specific factors affecting dissemination
2.7. Geographical distribution within the Union of the sexually 
compatible species (for environmental safety aspects)
2.8. In the case of plant species not normally grown in the Union 
description of the natural habitat of the plant, including information on 
natural predators, parasites, competitors and symbionts (for 
environmental safety aspects) 
2.9. Other potential interactions, relevant to the GM plant, of the plant 
with organisms in the ecosystem where it is usually grown, or used 
elsewhere, including information on toxic effects on humans, animals 
and other organisms (for environmental safety aspects)
(a) Description of the methods used for the genetic modification 
(b) Nature and source of vector used
3.1. Information relating to the genetic modification
3. Molecular Characterisation
2.3. Information concerning reproduction (for environmental safety aspects)
2.6. Dissemination (for environmental safety aspects)Part VII - Summary
(c) Source of donor nucleic acid(s) used for transformation, size and intended 
function of each constituent fragment of the region intended for insertion
3.2.1. Description of the trait(s) and characteristics which have been 
introduced or modified
(a) The copy number of all detectable inserts, both complete and partial 
(b) In the case of deletion(s), size and function of the deleted region(s)
(c) Sub-cellular location(s) of insert(s) (nucleus, chloroplasts, mitochondria, 
or maintained in a non-integrated form), and methods for its/their 
determination
(d) The organisation of the inserted genetic material at the insertion site
(e) In the case of modifications other than insertion or deletion, describe 
function of the modified genetic material before and after the modification, as 
well as direct changes in expression of genes as a result of the modification
(a) Information on developmental expression of the insert during the life cycle 
of the plant
(b) Parts of the plant where the insert is expressed
3.2.4. Genetic stability of the insert  and phenotypic stability of the GM plant 
(a) Mode(s) and/or rate of reproduction
(b) Dissemination
(c) Suvivability
(d) Other differences 
3.2. Information relating to the GM plant
3.2.2. Information on the nucleic acid(s) sequences actually inserted or deleted
3.2.3. Information on the expression of the insert
3.2.5. Information (for environmental safety aspects) on how the GM plant differs from the recipient plant in:
3.2.6. Any change to the ability of the GM plant to transfer genetic material to other organisms (for environmental 
safety aspects)Part VII - Summary
(a) Plant to bacteria gene transfer
(b) Plant to plant gene transfer:
4.1. Choice of the conventional counterpart and additional comparators
Description of the experimental design (Number of locations, growing 
seasons, geographical spread, replicates and number of commercial 
varieties in each location) and of the statistical analysis. 
4.3. Selection of material and compounds for analysis
4.4. Comparative analysis of agronomic and phenotypic characteristics
4.5. Effect of processing
5. Toxicology
(a) Toxicological testing of newly expressed proteins 
(b) Testing of new constituents other than proteins
(c) Information on natural food and feed constituents
(d) Testing of the whole GM food and feed
6. Allergenicity
(a) Assessment of allergenicity of the newly expressed protein
(b) Assessment of allergenicity of the whole GM plant
7. Nutritional assessment 
(a) Nutritional assessment of GM food
(b) Nutritional assessment of GM feed 
8. Exposure assessment - Anticipated intake/extent of use
9. Risk characterisation
10. Post-market monitoring of GM food or feed
4. Comparative Analysis
4.2. Experimental design and statistical analysis of data from field trials for comparative analysisPart VII - Summary
11. Environmental assessment
11.1. Mechanism of interaction between the GM plant and target 
organisms 
(a) Persistence and invasiveness
(b) Selective advantage or disadvantage
(c) Potential for gene transfer
(d) Interactions between the GM plant and target organisms
(e) Interactions of the GM plant with non-target organisms
(f) Effects on human health
(g) Effects on animal health 
(h) Effects on biogeochemical processes
(i) Impacts of the specific cultivation, management and harvesting techniques
11.3. Potential interactions with the abiotic environment
11.4 Risk characterisation
12. Environmental monitoring plan 
(a) General (risk assessment, background information) 
(b) Interplay between environmetnal risk assessment and monitoring 
(c) Case-specific GM plant monitoring (approach, strategy, method and 
analysis) 
(d) General surveillance of the impact of the GM plant (approach, strategy, 
method and analysis) 
(e) Reporting the results of monitoring
13. Detection and identification techniques for the GM plant
14. Information relating to previous releases of the GM plant (for ERA aspects)
11.2. Potential changes in the interactions of the GM plant with the biotic environment resulting from the 
genetic modification Part VII - Summary
(a) Notification number
(b) Conclusions of post-release monitoring
(c) Results of the release in respect to any risk to human health and the 
environment (submitted to the Competent Authority according to Article 10 of 
Directive 2001/18/EC)
(a) Release country
(b) Authority overseeing the release
(c) Release site
(d) Aim of the relaese
(e) Duration of the release
(f) Aim of post-releases monitoring
(g) Duration of post-releases monitoring
(h) Conclusions of post-releases monitoring
(i) Results of the release in respect to any risk on human health and the 
environment
14.1. History of previous releases of the GM plant notified under Part B of the Directive 2001/18/EC and 
under Part B of Directive 90/220/EEC by the same notifier  
14.2. History of previous releases of the GM plant carried out outside the Community by the same notifierAppendix B 
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APPENDIX B: EXAMPLES OF FIGURES AND TABLES FOR PART II 
This  appendix  contains  examples  of  the  types  of  figures  and  tables  that  may  be  included  in  an 
application. Figures and tables are useful to provide an overview of studies in the application and 
snap-shots of each study, to add clarity to parts of a study with illustrations, and to streamline the risk 
assessment process. These figures and tables should not be viewed as precise templates as the data in 
each application differs. They are non-binding, omission of certain details in the exemplar tables or 
figures does not mean these data are not necessary, for example, the fatty acid analysis in Table 2 
contains  only  a  limited  number  of  fatty  acids.  Other  formats  of  these  figures  and  tables  will  be 
accepted, provided that the same aim is achieved. 
Table of contents 
1.  Example of an overview table indicating the title of the studies, the section they relate to and the 
type of information………………………………………………………………………………...2 
2.  Example of study overview table………………………………………………………………….4 
A.  GM plant containing a single event ……………………………..………………………..4 
B.  GM plant containing stacked events ……………………………………………….……..8 
3.  Example of overview table on bioinformatic analyses…………………………………………...15 
A.  GM plant containing a single event …………………………………….…….….............15 
B.  GM plant containing stacked events ……………..............................................................16 
4.  Example of a summary table related to a field trial for the protein expression analysis….……...17 
5.  Example of a breeding tree………………………………………………………………….……18 
6.  Examples of Southern data representation………………………………………………………..19 
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Table 1:   Example of a general overview table of data provided in the Part II of an application indicating the title of the studies, the section they 
relate to and the type of information they contain. This table should be provided as a separate appendix. Every time additional information is provided, this 
table should be updated and provided as a separate appendix. 
SECTION  NAME  TITLE 
RELATED 
SECTION IN 
PART II 
AUTHOR NAMES 
ON THE STUDY 
TO BE KEPT 
CONFIDENTIAL 
(YES/NO) 
 
INFORMATION
1 
  Main text (no additional info needs to be added) 
Non-CI 
Appendices 
 
e.g. Appendix X  e.g. Molecular characterisation of insert   e.g. A.2.1    New document
2 
        From Apxx
3-flanking 
        Updated study
4 
         
         
         
         
CI Appendices 
 
         
         
         
         
         
         
         
References
5       
 
 
 
                                                       
1 Some additional information to clarify the way information can be provided is given in footnotes 
2 This analyses can be found in the current application 
3 This study has also been provided in the frame of applicationXX 
4 A study had been provided in the frame of a previous application but has been updated in the current application 
5 No description is expected, except for key studies they should be added (maximum 10) Appendix B 
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Table 2:   Example  of  application  overview  table  focussing  on  study  reports  based  on  an 
application  for  herbicide  tolerance  GM  maize.  This  table  should  be  provided  as  a  separate 
appendix. Every time additional information is provided, this table should be updated and provided as 
a separate appendix. 
A. GM plant containing single event  
APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Single event  Comparators 
  event name  conventional 
counterpart 
commercial 
varieties 
newly expressed proteins  protein A  protein B  n.a.  n.a. 
Traits      n.a.  n.a. 
Breeding tree  (Appendix xx Pxx)  (Appendix  xx 
Pxx) 
 
Scope 
1. Food 
   1.1 GM plants for food use 
   1.2 Food containing or consisting of GM plants 
   1.3 Food produced from GM plant s or containing ingredients produced from GM plants 
2. Feed 
   2.1 GM plants for feed use 
   2.2 Feed containing or consisting of GM plants 
   2.3 Feed produced from GM plants 
3. GM plants for environmental release 
   3.1 Import and processing 
 3.2 Seeds and plant propagating material for cultivation in Europe 
Anticipated uses and products  (Appendix xx page xx)     
 MOLECULAR CHARACTERISATION 
  Information on the zygosity of the insert in the to be commercialised plant e.g. F1 hybrid hemizygous for the newly introduced 
genes  
  Information on the biology of the crop (self- or cross-pollinator) 
Insert structure and backbone presence (sequence) 
(Appendix xx) 
  Number of Inserts & copy number of the newly introduced gene A gene B 
  No backbone sequence present or partial vector backbone present (including 
following elements x & y) 
  name of the gene promoter driving expression of gene A and gene B 
negative control 
used in Southern 
analyses:e.g.  near-
isogenic 
NGMx/NGMy or 
commercial hybrid xx 
n.a. 
Ref to sequence  
(Appendix xx) 
Bioinformatic analyses  
Ref to bioinformatic overview table 
(Appendix xx): Flanking sequence 
(Appendix xx): ORF analyses 
Stability/integrity (Segregation) 
(Appendix xx) Genetic stability 
  stable insertion in nucleus confirmed by PCR and Southern on x generations (Fn, 
BCx). 
(Appendix xx) Phenotypic stability 
negative control 
used in Southern 
and PCR 
analyses e.g. 
near-isogenic 
n.a. Appendix B 
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APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Single event  Comparators 
  event name  conventional 
counterpart 
commercial 
varieties 
  consistent expression level of proteins A and B in x generations (Fn, BCx).  
  segregation analysis of on x generations (Fn, BCx). 
NGMx/NGMy or 
commercial hybrid 
xx 
Protein expression  
Ref to protein field trial overview table 
(Appendix xx) Field trial year (production plan ID) 
-country, nr sites, x hybrid (NGMx(BCxFx)/NGMy & NGMz(BCxFx)/NGMy)  
- zygosity of the insert in the analysed plants and a detailed description on the grain content if 
segregation occurs 
-leaves (developmental stage xx and xx), roots, pith, silk, pollen, whole plants at anthesis stage 
and kernels. 
-treated and untreated with targeted herbicide regime 
(Appendix xx) Field trial year (production plan ID) 
-country, nr sites, (NGMx(BCxFx)/NGMy)  
-leaves (developmental stage xx and xx), roots (developmental stage xx and xx), whole plants at 
four growth stages, kernels, piths, silk, pollen. 
-treated and untreated with targeted herbicide regime 
control (e.g. 
near-isogenic 
NGMx/NGMy) 
used  to  test 
specificity  of 
antibody 
n.a. 
Other molecular studies 
(Appendix xx) e.g. RT-PCR on ORF3  negative  control 
e.g.  near-isogenic 
NGMx/NGMy 
n.a. 
Rationale  if  certain  studies  were  not  deemed  needed  or  not  in  line  with  EFSA  GMO  Panel 
guidelines 
 e.g. Genetic stability was only shown in 4 generations due to the long generation time of the species 
(see main text page xx) 
 COMPARATIVE ANALYSIS 
Compositional analysis 
(Appendix xx) Field trial year (country, nr sites, production plan ID) 
  NGMx(BCxFx)/NGMy (BCxFx) 
  Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
  nr parameter analyzed in forage  
o  Proximate (ash, fat, moisture, protein, carbohydrates, ADF, NDF) 
o  mineral (Ca, P) 
o  allergens 
  nr parameter analyzed  in grain  
o  proximates (ash, fat, moisture, protein, carbohydrates, ADF, NDF) 
o  minerals (Ca, copper, Fe,Mg, manganese, P, potassium, selenium, Na, Zn) 
o  amino acids composition (18) 
o  fatty acides (16:0 Palmitic, 18:0 Stearic, 18:1 Oleic, 18:2 Linoleic, 18:3 
Linolenic) 
o  vitamins (A, B1, B2, B3, B6, B9, E) 
o  secondary metabolites and anti nutrients (ferulic acid, p-coumaric acid, 
inositol, phytic acid, trypsin inhibitor, furfural, raffinose) 
o  allergens 
 
near-isogenic 
NGMx/ NGMy 
 
 
nr. commercial 
hybrid 
+ 
ranges of 
natural 
variation (ILSL, 
2006) (OECD, 
2002) 
 
(add info year-mon-date Appendix xx) Field trial year (country, nr sites, 
production plan ID) 
near-isogenic 
NGMz/ NGMy 
nr. commercial 
hybrid Appendix B 
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APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Single event  Comparators 
  event name  conventional 
counterpart 
commercial 
varieties 
  NGMx/NGMy(BCxFx) 
  treated or untreated with target herbicide  
  nr parameter analyzed in forage (as 200x) 
  nr parameter analyzed in grain (more than 200x) 
o  proximate (+ starch) 
o  minerals (as 200x) 
o  amino acids composition (as 200x) 
o  fatty acids (+ 20:0 arachidic, 20:1 eicosenoic, 22:0 behenic) 
o  vitamins (as 200x) 
o  secondary metabolites and anti nutrients (as 200x) 
  + 
ranges of 
natural 
variation (ILSL, 
2006) (OECD, 
2002) 
Agronomic traits & phenotypic stability 
(Appendix xx) Field trial year (country, nr sites, production plan ID) 
  NGMx/NGMy(BCxFx) 
  nr agronomic traits  
  nr disease trait were evaluated. Not all traits were recorded at all locations.  
near-isogenic 
NGMy/ NGMx 
nr. commercial 
hybrid 
(add info year-mon-date Appendix xx) statistical analysis 
  statistical code 
  raw data 
 TOXICITY 
Bioinformatics of newly expressed proteins to Toxin databases  
Ref to bioinformatic overview table 
  (Appendix xx) BLASTP to Genbank non-redundant xx 201x 
Equivalence between microbial recombinant protein vs. plant protein 
(Appendix xx) Amino acid comparison 
  alignment indicated on pxx 
 
(Appendix xx) comparison protein A produced by E.coli to the leaf extract 
  bacterial strain used for producing recombinant protein 
  plant tissue from which the native protein was extracted 
  list type of analysis (e.g., concentration, purity, immunoreactivity, molecular 
weight, glycosylation and N-terminal aa and insecticidal activity was determined by 
SDS-PAGE, western, peptide mass mapping analysis, N-terminal sequence, 
glycosylation analysis, insect bioassay, etc). 
 
(Appendix xx) protein A produced by E.coli vs the plant extract 
(Appendix xx) protein B produced by E.coli vs the plant extract 
  bacterial strain used for producing recombinant protein 
  plant tissue from which the native protein was extracted 
  list type of analysis (e.g., concentration, purity, immunoreactivity, molecular 
weight, glycosylation and N-terminal aa and insecticidal activity was determined by 
SDS-PAGE, western, peptide mass mapping analysis, N-terminal sequence, 
glycosylation analysis, insect bioassay, etc) 
leaf extract from 
e.g.,  a  negative 
segregant 
 
n.a. 
Acute oral toxicity test 
(Appendix xx) protein A 
  protein source: e.g., E.coli  
  duration: e.g., 14 days 
  dosage: e.g., 0 and 1250 mg protein / kg body weight 
  animals (species, number): e.g., inbred mice (nr. Female + nr. male) 
  negative control: e.g., corn oil 
(Appendix xx) protein B  
  as above 
Repeated-dose oral toxicity test Appendix B 
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APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Single event  Comparators 
  event name  conventional 
counterpart 
commercial 
varieties 
(Appendix xx) protein A 
  protein source: e.g., E.coli  
  duration: e.g., 14 days 
  dosage: e.g., 0, 200, 1000 and 5000 mg protein / kg body weight 
  animals (species, number): e.g., inbred mice (nr. Female + nr. male) 
  negative control: e.g., corn oil 
(Appendix xx) protein B 
  as above 
90-day animal feeding study 
(Appendix xx) 
  F2 grain NGMy/ NGMx(BCxFx) 
  dosage: e.g., 10 or 41.5% of grain 
  animals (species, number): e.g., inbred mice (Nr F + Nr M) 
  diet component analysis 
  statistical analysis: gm impact, gender impact 
near-isogenic 
NGMy/ NGMx 
nr. commercial 
hybrid 
Other toxicity studies 
(Appendix xx)     
Rationale  if  certain  studies  were  not  deemed  needed  or  not  in  line  with  EFSA  GMO  Panel 
guidelines 
e.g. why certain toxicity tests are not necessary (see main text page xx) 
 ALLERGENICITY 
Bioinformatics of newly expressed proteins to Allergen databases  
Reference to bioinformatic overview table 
  (Appendix xx) e.g., FARRP 201x 
Proteolytic degradation 
(Appendix xx) in vitro SGF digestibility assay (pH xx) on protein A 
(Appendix xx) in vitro SGF digestibility assay (pH xx) on protein B 
(Appendix xx) in vitro SIF digestibility assay on protein A 
(Appendix xx) in vitro SIF digestibility assay on protein B 
  specify the host e.g. bacterial strain used for producing recombinant protein 
In vitro IgE binding assay 
(Appendix xx)      
Other immunological studies 
(Appendix xx)      
Rationale  if  certain  studies  were  not  deemed  needed  or  not  in  line  with  EFSA  GMO  Panel 
guidelines 
e.g. why certain immunological tests are not necessary (see main text page xx) 
 NUTRITIONAL ASSESSMENT 
Exposure 
(Technical dossier pxx) anticipated intake of proteins A and B from consuming crop xx in EU 
(Appendix xx pxx) Exposure assessment for fatty acids 
  concentration of the fatty acids measured from refined oil 
  consumption data base 
  recipe calculation Appendix B 
 
  7 
APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Single event  Comparators 
  event name  conventional 
counterpart 
commercial 
varieties 
  population 
  dietary estimate (g/d, E%): average intake, percentile consumer 
  nutritional impact at EU level 
Nutritional assessment by animal study 
(Appendix xx) e.g. broiler study  
  F2 grain NGMx/ NGMy(BCxFx) 
  dosage 
  animals (species, number): e.g., each genotype used Nr F + Nr M [nr birds/pen x nr 
pens], in total nr 
  diet component analysis 
  statistical analysis: gm impact, gender impact 
isogenic 
NGMx/ NGMy 
nr. commercial 
variety 
Other nutritional studies 
(Appendix xx)  
Rationale  if  certain  studies  were  not  deemed  needed  or  not  in  line  with  EFSA  GMO  Panel 
guidelines 
e.g. why certain nutritional tests are not necessary (see main text page xx) 
 ERA 
please fill in the Appendices D, E, F, G 
Note:  1) for data generated in other relevant application, please indicate the EFSA application identification code. 
    2) please distinguish “not applicable (n.a.)” from “not provided (n.p.)”, for the latter a justification shall be included. 
    3) a laboratory study shall be always cleared referred in the table, a reference includes (author name, year, study ID). 
    4)NGMx/NGMy is a example of genetic background of a GM maize hybrid. 
    5)BCxFx refers to the number of backcrosses and the number of selfing during plant breeding. Appendix B 
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B. GM plant containing stacked events  
 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
newly expressed proteins    n.a.  n.a.       
traits    n.a.  n.a.       
Breeding tree  (Appendix xx page xx)  (Appendix xx page xx)         
Scope 
1. Food 
   1.1 GM plants for food use 
   1.2 Food containing or consisting of GM plants 
   1.3 Food produced from GM plant s or containing ingredients produced from GM plants 
2. Feed 
   2.1 GM plants for feed use 
   2.2 Feed containing or consisting of GM plants 
   2.3 Feed produced from GM plants 
3. GM plants for environmental release 
   3.1 Import and processing 
 3.2 Seeds and plant propagating material for cultivation in Europe 
Anticipated uses and products (Appendix xx Pxx) 
ISSUES CONSIDERED DURING THE SAFETY ASSESSMENT OF GM PLANTS CONTAINING STACKED EVENTS 
Assessment of interaction(s) 
(Appendix xx) 
list arguments in bullet points, indicate laboratory studies with clear reference 
Assessment of sub-combinations  
(Appendix xx) 
list arguments in bullet points, indicate laboratory studies with clear reference Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
 MOLECULAR CHARACTERISATION 
  Information on the zygosity of the insert in the to be commercialised plant e.g. F1 hybrid hemizygous for the newly introduced genes  
  Information on the biology of the crop (self- or cross-pollinator) 
Insert structure  
insert structure/backbone sequence   (Appendix xx) 
Integrity  inserts: 
via method 
 Control description  n.a.  Nr  of  inserts/nr  of 
copies/backbone 
Nr  of  inserts/nr  of 
copies/backbone 
… 
 
Sequence 
   E.g. See single   n.a.  n.a.   Ref  to  current  or 
previous dossier where 
the  studies  can  be 
found 
 Ref  to  current  or 
previous dossier where 
the  studies  can  be 
found 
… 
 
Bioinformatic analyses Ref to bioinformatic overview table 
Flanking sequence  Updated  in  this 
dossier/  up-to  date 
in  previous…  (see 
singles) 
n.a.  n.a.  Ref  to  current  or 
previous dossier where 
the  most  up-to-date 
studies can be found 
Ref  to  current  or 
previous dossier where 
the  most  up-to-date 
studies can be found 
… 
 
ORF analysis   Updated  in  this 
dossier/  up-to  date 
in  previous…  (see 
singles) 
n.a.  n.a.  Ref  to  current  or 
previous dossier where 
the  most  up-to-date 
studies can be found 
Ref  to  current  or 
previous dossier where 
the  most  up-to-date 
studies can be found 
… 
 
Stability/integrity 
Genotypic  (Appendix xx) 
Method & Number 
of generations 
 control  n.a.   Method & Number of 
generations 
 Method & Number of 
generations 
… 
 
Phenotypic  (Appendix  xx) 
Method & Number 
of generations 
   n.a.   Method & Number of 
generations 
 Method & Number of 
generations 
… 
 
Protein expression Ref to protein field trial overview table 
   (Appendix xx)   (Appendix xx)  n.a.  (Appendix xx)  (Appendix xx)  … Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
Year(s)  (+  location  and  nr  of  sites)  of 
studies in current application 
Year(s)  (+  location 
and nr of sites) 
Control used to test 
specificity of 
antibody 
Year(s) (+ location and 
nr of sites) 
 
Year(s)(+ location and 
nr of sites) 
 
 
List tissues that were analyzed  List  tissues  that 
were analyzed 
n.a.  n.a.  List  tissues  that  were 
analyzed 
List  tissues  that  were 
analyzed 
 
Other  relevant  info  (zygosity  of  the 
insert  in  the  analysed  plant, indicate if 
inserts  segregate  in  the  analysed 
grain/seed, specific treatment) 
specific treatment  n.a.  n.a.  specific treatment  specific treatment   
Raw/data production plan ID  Reference  n.a.  n.a.  Reference  Reference   
Data in related dossiers  n.a.  n.a.  n.a.  (APxx, Appendix xx) 
Year(s) (+ nr of sites)  
(APxx, Appendix xx) 
Year(s) (+ nr of sites)  
 
Other molecular studies 
             
Rationale if certain studies were not deemed needed or not in line with EFSA GMO Panel guidelines 
 COMPARATIVE ANALYSIS 
Compositional analysis 
(Appendix xx) Field trial year (country, 
nr. site, production ID)  
(Appendix xx) compositional analysis 
(Appendix xx) statistical analysis 
 
nr parameter in forage 
  NGMx/NGMy(BCxFx) 
  list parameters 
   
nr parameter in grain  
  B020x/B971x(BCxFx) 
  list parameters 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Statistical analysis 
  statistical 
code 
  raw data 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Statistical analysis 
  statistical 
code 
  raw data 
Nr.  commercial 
varieties 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Statistical analysis 
 
  statistical 
code 
  raw data 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
 
Statistical analysis 
  across location 
  per site 
 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
 
Statistical analysis 
  across location 
  per site 
 
… 
 
Agronomic traits & phenotypic stability Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
(Appendix xx) Field trial year (country, 
nr. site, production ID)  
 
(Appendix xx) agronomic study 
  NGMx/NGMy(BCxFx) 
  nr agronomic traits  
  nr disease trait 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Nr.  commercial 
varieties 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
Herbicide regime 
  sprayed 
  unsprayed 
  not applicable 
field  trial  (country,  nr.  of 
sites, production plan ID) 
… 
 
TOXICITY 
Bioinformatics of newly expressed proteins to Toxin databases  
Reference  to  bioinformatic  overview 
table 
  (Appendix xx) BLASTP to e.g., Genbank non-
redundant xx 201x 
Database  name  & 
version 
 n.a.  n.a.  Database  name  & 
version  of  the  last 
update 
Database  name  & 
version  of  the  last 
update 
… 
 
Equivalence between microbial recombinant protein vs. plant protein 
(Appendix  xx)  based  on  data  of  single 
events 
    
   n.a.  n.a.    bacterial strain 
used for producing 
recombinant protein 
  plant tissue from 
which the native 
protein was extracted 
  bacterial strain 
used for producing 
recombinant protein 
  plant tissue from 
which the native protein 
was extracted 
… 
   
Acute oral toxicity test 
(Appendix xx) assessment in light of data 
of single events   
  protein source 
  duration 
  dosage 
  animals (species, 
number) 
  negative 
control 
n.a.  n.a.    protein source 
  duration 
  dosage 
  animals (species, 
number) 
  protein source 
  duration 
  dosage 
  animals (species, 
number) 
… 
   Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
Repeated-dose oral toxicity test 
(Appendix xx) assessment in light of data 
of single events 
  protein source 
  duration 
  dosage 
  animals (species, 
number) 
  negative 
control 
n.a.  n.a.    protein source 
  duration 
  dosage 
  animals (species, 
number) 
  protein source 
  duration 
  dosage 
  animals (species, 
number) 
… 
   
90-day animal feeding study 
(Appendix xx)     diet component 
  duration 
  dosage 
  animals (species, 
number) 
  diet component 
  duration 
  dosage 
  animals (species, 
number) 
  diet component 
  duration 
  dosage 
  animals (species, 
number) 
   diet component 
  duration 
  dosage 
  animals (species, 
number) 
  diet component 
  duration 
  dosage 
  animals (species, 
number) 
… 
   
Other toxicity studies 
(Appendix  xx)  e.g.,  assessment  of 
synergistic  or  antagonistic  toxicity  by 
combining newly expressed proteins 
  protein source 
  duration 
  dosage 
  animals (species, 
number) 
  negative 
control 
n.a.  n.a.  n.a.  n.a.  … 
 
Rationale if certain studies were not deemed needed or not in line with EFSA GMO Panel guidelines 
ALLERGENICITY 
Bioinformatics of newly expressed proteins to Allergen databases  
Reference  to  bioinformatic  overview 
table 
  (Appendix xx) e.g., FARRP 201x 
Database  name  & 
version 
 n.a.  n.a.  Database  name  & 
version  of  the  last 
update 
Database  name  & 
version  of  the  last 
update 
… 
 
Proteolytic degradation Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
(Appendix xx) assessment in light of data 
of single events 
   n.a.  n.a.  specify  the  host  e.g. 
bacterial strain used for 
producing  recombinant 
protein 
  in vitro SGF 
  in vitro SIF 
specify  the  host  e.g. 
bacterial strain used for 
producing  recombinant 
protein 
  in vitro SGF 
  in vitro SIF 
… 
   
In vitro IgE binding assay 
(Appendix xx)              
Other immunological studies 
(Appendix xx)              
Rationale if certain studies were not deemed needed or not in line with EFSA GMO Panel guidelines 
 NUTRITIONAL ASSESSMENT 
Exposure 
(Technical  dossier  pxx)  anticipated  intake  of 
proteins A, B… from consuming crop xx in EU 
(Appendix  xx  pxx)  Exposure  assessment 
for fatty acids 
  concentration of the fatty acids measured 
from refined oil 
  consumption data base 
  recipe calculation 
  population 
  dietary estimate (g/d, E%): average intake, 
percentile consumer 
  nutritional impact at EU level 
   n.a.  n.a.       
Nutritional assessment by animal study 
(Appendix xx) e.g. broiler study    diet component 
  duration 
  dosage 
  animals (species, 
  diet component 
  duration 
  dosage 
  animals (species, 
  diet component 
  duration 
  dosage 
  animals (species, 
  diet component 
  duration 
  dosage 
  animals (species, 
  diet component 
  duration 
  dosage 
  animals (species, 
… 
   
 Appendix B 
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 APPLICATION IDENTIFICATION CODE (EVENT NAME) 
  Stacked event  Comparators for the stacked event  Single events (obligatory) / Parent events (if available) 
Event name  A x B x …  conventional 
counterpart 
commercial 
varieties 
A 
 
B 
 
… 
(add one column for 
each additional event) 
number)  number)  number)  number)  number) 
Other nutritional studies 
(Appendix xx)              
Rationale if certain studies were not deemed needed or not in line with EFSA GMO Panel guidelines 
 ERA 
please fill in the Appendices D, E, F, G 
Note:  1) for data generated in other relevant application, please indicate the EFSA application identification code. 
2) please distinguish “not applicable (n.a.)” from “not provided (n.p.)”, for the latter a justification shall be included. 
3) a laboratory study shall be always cleared referred in the table, a reference includes (author name, year, study ID). 
4) NGMx/NGMy is a example of genetic background of a GM maize hybrid. 
5) BCxFx refers to the number of backcrosses and the number of selfing during plant breeding. Appendix B 
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Table 3:   Example of overview table on bioinformatic analyses. This table/these tables should be included or in the main text, or in the specific studies of 
the Part II of an application, or as a separate appendix. In case the bioinformatic analysis is updated these tables should be amended.  
Since the risk assessment performed by the EFSA GMO Panel may not start immediately after validity for applications for GM plants including the scope 
cultivation and applications for GM plants containing stacked events for which single event(s) have not been risk assessed, for these types of applications, the 
completeness check of the bioinformatic analyses will be limited to checking if the application includes: (1) a summary of the results, (2) an overview of the 
studies, related to the different aspects (flanking sequences, ORFs, newly expressed proteins, see below), and (3) a clear and correct reference where the 
studies (including the outputs) can be found. In the case of applications for GM plants containing stacked events, it will be accepted that bioinformatic studies 
are not included in the technical dossier in case they have been summarised and properly referred to in the main text. Please note that other formats of 
overview tables will be accepted as long as the information to be included in the example formats is summarised. 
A. GM plant containing single event  
Flanking sequences (both against DNA and protein databases) 
General Database
1  Date
2  Algorithms
3 
Ref. to place 
in dossier
4  EST Database1*  Date2  Algorithms
3 
Ref. to place in 
dossier
4 
Nucleotide
1                    
Protein
1         
ORF analyses  insert-plant (a) /  insert-insert (b)* /  whole insert (c) 
Allergen database
1  Date
2  Algorithms
3 
Ref. to place 
in dossier
4 
General  (and 
toxin*) database1  Date2  Algorithms
3 
Ref. to place in 
dossier
4 
 (a)                      
Newly expressed proteins 
Allergen database
1  Date
2  Algorithms
3 
Ref. to place 
in dossier
4 
General  or  toxin-
database1  Date2  Algorithms
3 
Ref. to place in 
dossier
4 
Protein 1 
                       
Protein 2                 
1. e.g. Genbank non-redundant nucleotide, Genbank non-redundant protein, Genbank general/plant/species EST, FARRP vs. xx (including version and using official name) 
2. release date of the version of the database used for the analysis 
3. algorithm e.g. BLASTn, BLASTx, BLASTp, FASTA, ... and indicate if default settings were used and if not which parameter was adjusted 
4. application number, place in dossier (e.g. technical dossier, additional information with date); citation and internal reference number 
* include specifics in the table only when applicable and provided Appendix B 
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B. GM plant containing stacked events  
  Flanking sequences (both against DNA and protein databases) 
  
General 
Database
1  Date
2  Algorithms
3 
Ref.  to  place 
in dossier
4  EST Database
1*  Date
2  Algorithms
3 
Ref.  to  place  in 
dossier
4 
event 1  Nucleotide
1                   
  Protein
1               
event 2  Nucleotide
1                   
  Protein
1               
event 3  Nucleotide
1                   
  Protein
1               
  ORF analyses  insert-plant (a) /  insert-insert (b)* /  whole insert (c) 
  
Allergen 
database
1  Date
2  Algorithms
3 
Ref.  to  place 
in dossier
4 
General  (and 
toxin*) database
1  Date
2  Algorithms
3 
Ref.  to  place  in 
dossier
4 
event 1 (a)                         
event 1 (b)                 
event 2                         
event 3                         
  Newly expressed proteins 
  
Allergen 
database
1  Date
2  Algorithms
3 
Ref. to place in 
dossier
4 
General or toxin-
database
1  Date
2  Algorithms
3 
Ref.  to  place  in 
dossier
4 
protein 1                         
protein 2                         
protein...                         
                 
1. e.g. Genbank non-redundant nucleotide, Genbank non-redundant protein, Genbank general/plant/species EST, FARRP vs. xx (including version and using official name 
2. release date of the version of the database used for the analysis 
3. algorithm e.g. BLASTn, BLASTx, BLASTp, FASTA, ... and indicate if default settings were used and if not which parameter was adjusted 
4. application number, place in dossier (e.g. technical dossier, additional information with date); citation and internal reference number 
* include specifics in the table only when applicable and providedAppendix B 
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Table 4:   Example  of  a  summary  table  related  to  a  field  trial  for  the  protein  expression 
analyses. This table/these tables should be included in the specific study reports of the Part II of an 
application  
For  each  field  trial  (site)  carried  out  to  analyse  the  protein  expression  levels  of  the  GM  plant 
(including the controls such as GM plants containing single/related stacked events and/or non-GM 
comparator) a summary data sheet must be filled out. Therefore in one application multiple sheets may 
be required. Consider including tables for field trials described in previous or related applications 
submitted to EFSA. 
Field trial ID 
Protein(s) analysed  A  B  … 
Method of analysis (indicate if 
methods are identical between 
different field trials) 
     
Season       
Country/state/region (nr of sites)       
GM analysed with identification 
code, generation and genetic 
background 
     
Comparator(s) (non-GM; single 
events; parental lines-including 
genetic background) 
     
GM specific treatment(s)(such as 
specific herbicide) 
     
Tissues sampled/developmental 
stage (number of replicates) 
     
All tissues were analysed for each 
sites (if not please indicate) 
     
Report reference       
Production plan reference       
Raw data reference and kind of 
statistical analyses  
     
Reference where argumentation of 
choose of sites can be found 
     
Reference where argumentation of 
choose of tissues can be found 
     Appendix B 
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Figure 1:   Example of a breeding tree. This figure should be included or in the main text, or as a separate annex, if applicable. In case an additional 
generation was created and used in a study the figure should be amended.   Appendix B 
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Examples of Southern data representation 
Similar figures and tables should be included or in the main text, or in the specific study report. 
Table 5:   A summary of genetic elements on the plasmid and in the insert 
Genetic 
element 
Size  Location  Description, function and reference   
         
         
 
 
Figure 2:   A schematic representation of the insert 
To  support  the  Southern  analysis  EFSA  requests  that  a  schematic  overview  of  the  insert  (final 
structure in the plant including any rearrangements/duplications/deletions) showing the position of the 
genetic elements, restriction sites, different probes/primers and the length of the different expected 
fragments is included. 
Table 6:   A table with expected and observed fragments, including the information in which 
figure they can be found. 
  Probe 1  Probe 2 
  Restriction 
enzyme(s) 
combination A 
Restriction 
enzyme(s) 
combination B 
Restriction 
enzyme(s) 
combination A 
Restriction 
enzyme(s) 
combination B 
Expected fragment         
Observed band         
Figure         
Please provide this for both samples and positive controls.   Appendix C 
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EFSA identification code for the application (event name) 
 
Appendix C1  
Schematic summary of data for field or greenhouse trial for agronomic and phenotypic 
characteristics within a season (single event) 
 
A schematic summary should be provided for each field trial conducted for the comparative 
analysis of agronomic and phenotypic characteristics. 
It should be stored in the folder Appendices. 
 
Study report of field trial (e.g. Appendix  
X or author et al. (year)):  
 
Season (year) and dates:  
Location (country):  
Number of sites: 
Number of replicates: 
Type of plot design: 
Statistical power analysis: specify the name of the 
Appendix F ERA statistical design and analysis 
Field trial design:                                   same as field trial for compositional analysis 
                                                                 different  
                                
Field trial objective: 
 
 
 
1. Information on the tested plant material  
Plant material  Identification code in study report  Replicates 
GM plant      
     
Comparator(s)  
1.      
….     
Reference varieties 
1.       
…     
 
 
3. Treatments  
Treatment Code  Genotype 
and name 
Specification of 
treatment (herbicide, 
insecticide, other) 
…  … 
1. Treatment 1         
….         
n. Treatment n         
 
   Appendix C 
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4. Information on agronomic and phenotypic characteristics (Field trials) 
Agronomic 
characteristic 
Evaluation 
time 
Evaluation description 
Please specify how observations were 
evaluated and quantified (e.g. unit of 
measurement) 
Raw data 
provided 
1. Plant establishment 
and vigour 
     Yes 
  No 
 
2. Time of flowering 
and maturity 
     Yes 
  No 
3. Growth       Yes 
  No 
4. Plant height       Yes 
  No 
5. Dry matter 
production 
     Yes 
  No 
6. Seed       Yes 
  No 
7. Yield 
characteristics 
     Yes 
  No 
8. Vernalisation 
requirement 
     Yes 
  No 
9. Attractiveness to 
pollinators 
     Yes 
  No 
10. Pollen shed & 
viability  
     Yes 
  No 
11. Pollen 
compatibility & 
morphology 
     Yes 
  No 
12. Others       Yes 
  No 
 
5. Information on biotic and abiotic stressor(s) tested  
Biotic or abiotic stressors  Characteristics analysed  Raw data 
provided 
1. Insect incidence 
 
   Yes 
  No 
2. Diseases observation     Yes 
  No 
3. Abiotic stressors  
 
   Yes 
  No 
4. Others     Yes 
  No 
 
6. Dormancy and germination assessment and pollen morphology and viability assessment  
  Dormancy and germination  Pollen morphology and viability   Appendix C 
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Reference to study     
Type of study     
Control     
Germination endpoint     
Replicates     
Summary of analyses 
Differences observed     
Biological relevance     
…     
Conclusions     
 
For EFSA use     
 
 
7. Summary of analysis from Tables 1 to 6 
Agronomic and phenotypic characteristics   Environmental observations 
Statistically 
significant 
differences 
Please 
specify 
Biological 
relevance 
Please 
specify 
Differences 
observed 
Please 
specify 
Biological 
relevance 
Please 
specify 
Combined 
sites 
  Combined 
sites 
  Combined 
sites 
     
Individual 
sites 
  Individual 
sites 
  Individual 
sites 
     
…    …    …       
Conclusions   
 
For EFSA use   
   Appendix C 
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Appendix C2  
Schematic summary of data for field or greenhouse trial for agronomic and phenotypic 
characteristics within a season (GM plant containing stacked transformation events) 
 
A schematic summary should be provided for each field trial conducted for the comparative 
analysis of agronomic and phenotypic characteristics. 
It should be stored in the folder Appendices. 
 
Study report of field trial (e.g. 
Appendix X or author et al. (year)):  
 
Season (year) and dates:  
Location (country):  
Number of sites: 
Number of replicates: 
Type of plot design: 
Statistical power analysis: specify the name of 
the Appendix F ERA statistical design and analysis 
Field trial design:                                   same as field trial for compositional analysis 
                                                                 different  
                                
Field trial objective: 
 
 
 
1. Information on the tested plant material  
Plant material  Identification code in study report  Replicates 
GM plant containing 
stacked events ABC 
   
GM single event A     
GM single event B     
GM single event C     
…     
Comparator(s)  
1.      
….     
Reference varieties 
2.       
…     
 
3. Treatments  
Treatment Code  Genotype 
and name 
Specification of 
treatment (herbicide, 
insecticide, other) 
…  … 
1. Treatment 1         
….         
n. Treatment n         
   Appendix C 
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4. Information on agronomic and phenotypic characteristics 
Agronomic 
characteristic 
Evaluation 
time 
Evaluation 
description  
Please specify how 
observations were 
quantified (e.g. unit 
of measurement) 
Raw data 
provided 
Comparison data 
single/stacked events 
1. Plant 
establishment 
and vigour 
   
 Yes 
  No 
 
Please specify if 
observations differed 
from data obtained on 
each single event 
(including assessment 
of biological 
relevance) 
2. Time of 
flowering and 
maturity 
   
 Yes 
  No 
 
3. Growth       Yes 
  No 
 
4. Plant height       Yes 
  No 
 
5. Dry matter 
production 
     Yes 
  No 
 
6. Seed       Yes 
  No 
 
7. Yield 
characteristics 
     Yes 
  No 
 
8. Vernalisation 
requirement 
     Yes 
  No 
 
9. 
Attractiveness 
to pollinators 
     Yes 
  No 
 
10. Pollen shed 
& viability  
     Yes 
  No 
 
11. Pollen 
compatibility & 
morphology 
     Yes 
  No 
 
12. Others       Yes 
  No 
 
 
 
5. Information on biotic and abiotic stressor(s) tested  
Biotic or abiotic 
stressors 
Characteristics analysed  Raw data 
provided 
Comparison data 
single/stacked events 
1. Insect 
incidence 
   Yes 
  No 
Please specify if 
observations differed   Appendix C 
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  from data obtained on 
each single event 
2. Diseases 
observation 
   Yes 
  No 
 
3. Abiotic 
stressors  
 
   Yes 
  No 
 
4. Others     Yes 
  No 
 
 
6. Dormancy and germination assessment and pollen morphology and viability assessment  
  Dormancy and germination  Pollen morphology and viability 
Reference to study     
Type of study     
Control     
Germination endpoint     
Replicates     
Summary of analyses 
Differences observed     
Biological difference     
…     
Conclusions     
 
For EFSA use     
 
7. Summary of analysis from Tables 1 to 6 
Agronomic and phenotypic characteristics 
(see 4.) 
Environmental observations 
(see 5. and 6.) 
Statistical 
differences 
Please 
specify 
Biological 
relevance 
Please 
specify 
Differences 
observed 
Please 
specify 
Biological 
relevance 
Please 
specify 
Combined 
sites 
  Combined 
sites 
  Combined 
sites 
     
Individual 
sites 
  Individual 
sites 
  Individual 
sites 
     
…    …    …       
Conclusions   
 
For EFSA use   
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EFSA identification code for the application (event name) 
 
Appendix D  
 
Schematic summary of information for Insect Resistance Management  
 
Appendix E is requested for applications of GM insect resistant plants with the scope “seeds and plant 
propagating material for cultivation in the EU. The compiled appendix should be stored in the folder 
Appendices, subfolder ERA_Appendices D to F. 
 
1. Information on the target specific spectrum 
List of target insect species  
1. [name target organism] 
2.  
n. 
 
2. IRM plan and structure 
The IRM plan is    
          High dose/refuge strategy   Yes      No 
          Medium to low dose / refuge strategy   Yes      No 
Data on concentration of the insecticidal protein(s) in the GM plant are provided   Yes      No 
Data on proportion of target insects killed by the GM plant are provided   Yes      No 
Size of the refuge provided   Yes      No 
The IRM plan includes    
         A monitoring for any potential evolution of resistance   Yes      No 
         An educational programme   Yes      No 
         A remedial action plan   Yes      No 
 
3. Underlying assumptions  
Data on occurrence of resistance alleles in target insect population are provided   Yes      No 
Data on frequency of resistance alleles to the insecticidal proteins are provided    Yes      No 
If not provided, data are provided on 
o  Efficacy of the GM plant in controlling target insects 
o  Baseline susceptibility in the target insect 
 
 Yes      No 
 Yes      No 
Mating occur randomly between resistant and susceptible insects    Yes      No 
Data on mating and dispersal behaviour are provided   Yes      No  
Appendix D 
 
2 
 
Data on inheritance of resistance alleles (dominant, partially or fully recessive), 
including dominance value h, are provided  
 Yes      No 
Duration (i.e. number of generations) of susceptibility of target insects is considered   Yes      No 
Modelling prediction are used   Yes      No 
   Appendix E 
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EFSA identification code for the application (event name) 
 
 
Appendix E  
Schematic summary of NTO studies (laboratory, greenhouse, field trials) 
 
This Appendix is structured in the following four parts: 
 
  Part 1: Overview of NTO studies performed or commissioned by the applicant to support the NTO risk assessment 
  Part 2: Overview of NTO studies published in peer-reviewed journals and used by the applicant in support of the NTO risk assessment 
  Part 3: Summary of confined studies performed or commissioned by the applicant to support the NTO risk assessment 
  Part 4: Summary of field studies performed or commissioned by the applicant to support the NTO risk assessment 
 
The completed Appendix should be included in the folder Appendices, subfolder ERA_Appendices D to F. 
   Appendix E 
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PART 1 – Overview of NTO studies performed or commissioned by the applicant to support the NTO risk assessment 
 
 
Invertebrates 
Others 
(e.g., fish, birds, 
microorganisms) 
Natural enemies 
(predators & parasitoids)  Pollinators 
Herbivores 
(including species of 
conservation concern) 
Decomposers 
Type  Reference  Type  Reference  Type  Reference  Type  Reference  Type  Reference 
Study A  Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study B  Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study C  Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study D  Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
                     
For 
EFSA 
use 
                     Appendix E 
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PART 2 – Overview of NTO studies published in peer-reviewed journals and used by the applicant in support of the NTO risk assessment 
 
 
Invertebrates 
Others 
(e.g., fish, birds, 
microorganisms) 
Natural enemies 
(predators & parasitoids)  Pollinators 
Herbivores 
(including species of 
conservation concern) 
Decomposers 
Type  Reference  Type  Reference  Type  Reference  Type  Reference  Type  Reference 
Study A  Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1a 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study B  Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify 
appendix X or 
author et al. 
(year) 
Tier 1b 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study C  Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify 
appendix X or 
author et al. 
(year) 
Tier 2 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
Study D  Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify 
appendix X or 
author et al. 
(year) 
Tier 3 
Specify appendix 
X or author et al. 
(year) 
...  ...  ...  ...  ... 
                     
For 
EFSA 
use 
                     Appendix E 
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PART 3 – Summary of confined studies performed or commissioned by the applicant to support the NTO risk assessment (note: the table is to be 
completed for each funcional group studied) 
 
Criteria  Natural enemies (predators & parasitoids) / pollinators / herbivores / decomposers / others (e.g., cultural services, fish, 
birds, microorganisms) 
Reference  Specify appendix X or author et al. 
(year) 
Specify appendix X or author et al. 
(year) 
Specify appendix X or author et al. 
(year) 
Type of study  Tier 1a  Tier 1b  Tier 2 
Hypothesis under test  Specify in words  Specify in words  Specify in words 
Effects observed  Report observed effects (if any)  Report observed effects (if any)  Report observed effects (if any) 
Species name (Order: Family)  Specify (e.g., Poecilus cupreus 
(Coleoptera: Carabidae))  Specify  Specify 
Common name  Specify  Specify  Specify 
Species of conservation 
concern (e.g., rare and 
protected species, or species 
of aesthetic or cultural value) 
Specify  Specify  Specify 
Focal or surrogate species  Specify  Specify  Specify 
Source of test organisms  In-house colony / Purchased from 
commercial suppliers / Field collected 
In-house colony / Purchased from 
commercial suppliers / Field collected 
In-house colony / Purchased from 
commercial suppliers / Field collected 
Development stage of test 
organism  Specify  Specify  Specify 
Measurement endpoints  Specify measurement endpoints (e.g., 
survival, development rate, fertility) 
Specify measurement endpoints (e.g., 
survival, development rate, fertility) 
Specify measurement endpoints (e.g., 
survival, development rate, fertility) 
Test duration  Specify  Specify  Specify 
Test substance  Specify (e.g., pure Cry1Ab protein)  Specify transformation event + plant 
tissue (e.g., pollen, leaves, roots) 
Specify transformation event + plant 
tissue (e.g., pollen, leaves, roots) 
Expression level of novel trait  Specify for relevant plant part (e.g., 
μg/g Cry1Ab dry weight in pollen) 
Specify for relevant plant part (e.g., 
μg/g Cry1Ab dry weight in pollen) 
Specify for relevant plant part (e.g., 
μg/g Cry1Ab dry weight in pollen) 
Nominal dose of test 
substance, with unit  Specify (e.g.,  g/mL)  Specify (e.g.,  g/mL)  Specify (e.g.,  g/mL) if relevant 
Purity of test substance   Specify purity level (e.g., 95%)  NA  NA 
Bioequivalence of test 
substance 
Specify if bioequivalence was 
demonstrated and, if so, how 
Specify if bioequivalence was 
demonstrated and, if so, how (if no 
event-specific material is used) 
Specify if bioequivalence was 
demonstrated and, if so, how (if no 
event-specific material is used) 
Biological activity of test  Specify if biological activity was  Specify if biological activity was  Specify if biological activity was   Appendix E 
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substance before and after 
preparation of diet 
demonstrated and, if so, how (note: if 
biological activity was demonstrated 
before the assay was conducted, then 
describe storage conditons) 
demonstrated and, if so, how note: if 
biological activity was demonstrated 
before the assay was conducted, then 
describe storage conditons) 
demonstrated and, if so, how (if 
relevant) 
Stability of test substance   Specify level of stability and how it was 
determined 
Specify level of stability and how it was 
determined 
Specify level of stability and how it was 
determined (if relevant) 
Exposure of test organisms to 
test substance 
Specify level of exposure (e.g., 
maximum hazard dose, using expected 
environmental concentration based on 
expression data generated in EU field 
trials) 
Specify level of exposure  Specify level of exposure 
Route of in-field exposure  Specify  Specify  Specify 
Feeding conditions  Choice / No choice / Ad libitum / Fixed 
dose 
Choice / No choice / Ad libitum / Fixed 
dose 
Choice / No choice / Ad libitum / Fixed 
dose 
Negative control  Specify negative control(s) used  Specify negative control(s) used (e.g., 
near-isogenic line) 
Specify negative control(s) used (e.g., 
near-isogenic line) 
Positive control  Specify positive control(s) used  Specify positive control(s) used (if 
relevant) 
Specify positive control(s) used (if 
relevant) 
Number of replications   Specify   Specify   Specify  
Number of test organisms per 
treatment  Specify   Specify   Specify  
Number + nature of 
treatments  Specify  Specify  Specify 
Statistical power determined 
prospectively  Yes / No  Yes / No  Yes / No 
Reference to Appendix G 
ERA statistical design and 
analysis 
Specify the name of the Appendix  Specify the name of the Appendix  Specify the name of the Appendix 
       
For EFSA use       
   Appendix E 
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PART 4 – Summary of field studies performed or commissioned by the applicant to support the NTO risk assessment (note: the table is to be 
completed for each single field experiment) 
 
Criteria  Appendix X or author et al. (year) 
Hypothesis under test  Specify in words 
Functional groups for which 
comprehensive data were 
obtained 
Natural enemies 
(predators & 
parasitoids):  
Yes / No 
Pollinators: 
Yes / No  
Herbivores: 
Yes / No  
Decomposers: 
Yes / No  
Others (e.g., cultural 
services, fish, birds, 
microorganisms): 
Yes / No 
Abundant species 
List most abundant 
species for which 
comprehensive data 
were recorded 
List most abundant 
species for which 
comprehensive data 
were recorded 
List most abundant 
species for which 
comprehensive data 
were recorded 
List most abundant 
species for which 
comprehensive data 
were recorded 
List most abundant 
species for which 
comprehensive data 
were recorded 
Measurement endpoints 
Specify variables 
recorded, with units 
(e.g., abundance) 
Specify variables 
recorded, with units 
(e.g., abundance) 
Specify variables 
recorded, with units 
(e.g., abundance) 
Specify variables 
recorded, with units 
(e.g., abundance) 
Specify variables 
recorded, with units 
(e.g., abundance) 
Effects observed  Report which effects 
(if any) were observed 
Report which effects 
(if any) were observed 
Report which effects 
(if any) were observed 
Report which effects 
(if any) were observed 
Report which effects 
(if any) were observed 
Location  Specify continent, country, region and nearby city 
Study year  Specify 
Number of cropping seasons 
+ years covered  Specify 
Duration per growing season  Specify 
Single plot size  Specify (in hectares) 
Number of replications  Specify (e.g., number of plots, blocks, fields) 
Experimental/plot design  Specify (e.g., split-plots, random blocks, separate fields) 
Buffer size + nature  Specify (e.g., dimesion of borders surrounding the plots, interplot distances, type of buffer (e.g., plant species, bare ground)) 
Sampling methods 
Specify (e.g., pitfall 
traps, sweep netting, 
sticky traps, visual 
counts) 
Specify   Specify   Specify   Specify  
Sampling frequency  Specify   Specify   Specify   Specify   Specify  
Sampling pattern  Specify (e.g., 
intersects, random)  Specify   Specify   Specify   Specify  
GM event + variety name  Specify (transformation event of the crop tested + transgenic hybrid or variety name) 
Management context for  Specify active substances applied as well as timing and frequency of application (including sprays, soil granules or seed coating)   Appendix E 
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GM plant 
Conventional counterpart  Specify (e.g., near-isogenic line) 
Reference varieties  Specify name of reference varieties (if used) 
Management context for 
comparators  Specify active substances applied as well as timing and frequency of application (including sprays, soil granules or seed coating) 
Biodiversity estimates  Specify which ones (if appropriate) 
Reference to Appendix G 
ERA statistical design and 
analysis 
Specify the name of the Appendix 
           
For EFSA use           
   Appendix F 
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EFSA identification code for the application (event name) 
XXXX 
 
Appendix F  
Schematic summary of statistical design and analysis for each ERA study  
 
A schematic summary should be provided for each study conducted for the environmental risk assessment. 
All complied appendices should be included in the folder Appendices, subfolder ERA_Appendices D to F.  
 
Study report  
(e.g. [author] et al. (YYYY)):  
 
Field trial                                                             
Semi-field trial                                                    
Laboratory                                                          
Tier study                      tier 1a    tier 1b      tier 2      tier 3      
Equivalence test                                                   
Difference test                                                      
 
1. Presentation of data  Comments  Prov
ided 
Not 
prov
ided 
Not 
relev
ant 
Results are clearly presented, using standardized 
scientific units 
       
Raw data are provided         
Programming code used for the statistical 
analysis are present in an edible form 
       
Test materials are randomized to the 
experimental units 
       
The study is performed in accordance with 
international standards and protocols 
       
An experimental design protocol is provided         
An statistical analysis protocol is provided         
The mean, confidence limits and all equivalence 
limits are displayed on a graph 
       
 
 
 
         
2. Requirement for General Statistical 
Principles 
       
List explicitly in words all the questions that the 
study was designed to address 
 
       
Re-stated each question in formal terms, 
including precise null hypothesis that was tested 
to answer the question 
 
     
Clear description and justification of each 
assumptions made 
       
A proof of difference is provided           Appendix F 
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A proof of equivalence is provided         
For studies that use extra comparators, separate 
difference tests (between the GM plant and each 
of its different comparators) and separate 
equivalence tests (between the GM plant and 
each of its different comparators) are reported 
similarly 
 
     
 
 
3. Requirement for each measurement endpoint       
Clear description of each measurement endpoint 
are provided 
 
       
“Limits of concern” for each measurement 
endpoints are described 
       
If limits of concern for lower-tier studies are 
less than for higher-tier studies, justification is 
provided 
 
     
Effect size desired to detect with the study is 
given and justification is provided 
       
Minimum effect size relevant on the receiving 
environment(s) given and justification provided 
       
Statement on how the chosen effect size relates 
to the limit of concern through the minimum 
relevant ecological effect that is deemed 
biological relevant is provided 
 
     
When many measurement endpoints have been 
included in a study (e.g. where the endpoints 
represent several NTO species), the results of all 
endpoints for which sufficient records have 
been obtained are reported, not just those 
deemed to be of particular biological or 
statistical interest. 
 
 
     
 
 
4. Requirement for equivalence and difference test       
For the equivalence test, limit of concern are 
stated explicitly 
 
       
Statistical power if given         
The difference test has sufficient statistical 
power and justification are provided 
       
Power of each measurement endpoint of each 
difference test are provided at the planning stage 
of the study 
 
     
 
 
5. Additional requirement for field trials       
Minimum levels of abundance of each taxa 
samples are described and justified (NTO field 
trials) 
         Appendix F 
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The level of within-site replication is linked to 
the power analysis 
       
Justification of the selection of the different 
sites for the field trials is provided 
       
Each field trial is replicated over at least two 
years, each field trial over at least three sites. If 
not, justification is provided 
 
     
Field trials are performed in Europe         
Field trials are not performed in Europe and 
justification are provided 
       
 
 
6. Reporting       
All significant differences observed are reported 
and discussed; focusing on their biological 
difference 
 
       
For simultaneous texts of difference and 
equivalence, each outcome from the graph is 
categorized and the respective appropriate 
conclusion drawn. 
 
     
Analysis addressed all field trials 
simultaneously and is based on the full dataset 
from all sites 
 
     
Each analysis has the potential to identify any 
interactions between sites and years and the test 
materials;  for  each  measurement  endpoint 
studied,  explicit  statement  concerning  the 
presence or absence of any such interactions is 
provided; if interactions are found, the possible 
reasons for their existence and the implications 
for  the  inferences  drawn  from  the  trials  are 
discussed. 
 
     
A table or graph giving, for each site and year 
and  for  each  (transformed)  measurement 
endpoint,  the  means  and  standard  errors  of 
means  of  the  GM  plant  and  its  conventional 
counterpart(s),  and  any  other  test  material, 
where applicable is provided. 
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